BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-409. [PMID: 10940279 DOI: 10.1136/gut.47.3.404] [Cited by in Crossref: 485] [Cited by in F6Publishing: 463] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, Wolf JL, Cheifetz AS, Goldsmith JD, Moss AC. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11:991-996. [PMID: 23591275 DOI: 10.1016/j.cgh.2013.02.030] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 9.2] [Reference Citation Analysis]
2 Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 2018;67:43-52. [PMID: 27802155 DOI: 10.1136/gutjnl-2016-312293] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
3 Randall K, Henderson N, Reens J, Eckersley S, Nyström AC, South MC, Balendran CA, Böttcher G, Hughes G, Price SA. Claudin-2 Expression Levels in Ulcerative Colitis: Development and Validation of an In-Situ Hybridisation Assay for Therapeutic Studies. PLoS One 2016;11:e0162076. [PMID: 27598247 DOI: 10.1371/journal.pone.0162076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
4 Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11:713-719. [PMID: 16043985 DOI: 10.1097/01.mib.0000172807.26748.16] [Cited by in Crossref: 82] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
5 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
6 Kuznetsov NV, Zargari A, Gielen AW, von Stein OD, Musch E, Befrits R, Lofberg R, von Stein P. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol 2014;14:79. [PMID: 24758565 DOI: 10.1186/1471-230X-14-79] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
7 Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L. Comparing histological activity indexes in UC. Gut. 2015;64:1412-1418. [PMID: 25246423 DOI: 10.1136/gutjnl-2014-307477] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 8.8] [Reference Citation Analysis]
8 McGowan I, Cranston RD, Mayer KH, Febo I, Duffill K, Siegel A, Engstrom JC, Nikiforov A, Park SY, Brand RM, Jacobson C, Giguere R, Dolezal C, Frasca T, Leu CS, Schwartz JL, Carballo-Diéguez A. Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. PLoS One 2016;11:e0158310. [PMID: 27362788 DOI: 10.1371/journal.pone.0158310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Stallard L, Hussey S. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor. Front Pediatr 2021;9:678132. [PMID: 34249815 DOI: 10.3389/fped.2021.678132] [Reference Citation Analysis]
10 Dekkers N, Westerouen van Meeteren M, Wolterbeek R, Farina Sarasqueta A, Laleman W, Inderson A, Desschans B, van Hoek B, Sebib Korkmaz K, Vermeire S, Maljaars J. Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis? Dig Liver Dis 2020;52:528-33. [PMID: 32147286 DOI: 10.1016/j.dld.2020.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Monteleone G, Pallone F, Caprioli F. Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opin Investig Drugs 2013;22:1123-32. [PMID: 23802627 DOI: 10.1517/13543784.2013.813931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Jairath V, Peyrin-biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-bressenot A, Stitt LW, Shackelton LM, Khanna R, D’haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut 2019;68:1162-8. [DOI: 10.1136/gutjnl-2018-316702] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
14 Garg M, Royce SG, Tikellis C, Shallue C, Sluka P, Wardan H, Hosking P, Monagle S, Thomas M, Lubel JS, Gibson PR. The intestinal vitamin D receptor in inflammatory bowel disease: inverse correlation with inflammation but no relationship with circulating vitamin D status. Therap Adv Gastroenterol. 2019;12:1756284818822566. [PMID: 30719077 DOI: 10.1177/1756284818822566] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
15 Hussein RM, Saleh H. Promising therapeutic effect of gold nanoparticles against dinitrobenzene sulfonic acid-induced colitis in rats. Nanomedicine (Lond) 2018;13:1657-79. [PMID: 30085904 DOI: 10.2217/nnm-2018-0009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Development and validation of the Nancy histological index for UC. Gut. 2017;66:43-49. [PMID: 26464414 DOI: 10.1136/gutjnl-2015-310187] [Cited by in Crossref: 152] [Cited by in F6Publishing: 135] [Article Influence: 21.7] [Reference Citation Analysis]
17 Vos ACW, Wildenberg ME, Arijs I, Duijvestein M, Verhaar AP, de Hertogh G, Vermeire S, Rutgeerts P, van den Brink GR, Hommes DW. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro: . Inflammatory Bowel Diseases 2012;18:401-8. [DOI: 10.1002/ibd.21818] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 10.7] [Reference Citation Analysis]
18 Adamina M, Feakins R, Iacucci M, Spinelli A, Cannatelli R, D'Hoore A, Driessen A, Katsanos K, Mookhoek A, Myrelid P, Pellino G, Peros G, Tontini GE, Tripathi M, Yanai H, Svrcek M. ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology. J Crohns Colitis 2021;15:1089-105. [PMID: 33428711 DOI: 10.1093/ecco-jcc/jjab011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther. 2015;42:957-967. [PMID: 26304292 DOI: 10.1111/apt.13375] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
20 Andreadou I, Papalois A, Triantafillidis JK, Demonakou M, Govosdis V, Vidali M, Anagnostakis E, Kourounakis PN. Beneficial effect of a novel non-steroidal anti-inflammatory agent with basic character and antioxidant properties on experimental colitis in rats. European Journal of Pharmacology 2002;441:209-14. [DOI: 10.1016/s0014-2999(02)01410-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Szkaradkiewicz A, Marciniak R, Chudzicka-strugała I, Wasilewska A, Drews M, Majewski P, Karpiński T, Zwoździak B. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp 2009;57:291-4. [DOI: 10.1007/s00005-009-0031-z] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 5.6] [Reference Citation Analysis]
22 Maeda Y, Ohtsuka K, Kudo SE, Wakamura K, Mori Y, Ogata N, Wada Y, Misawa M, Yamauchi A, Hayashi S, Kudo T, Hayashi T, Miyachi H, Yamamura F, Ishida F, Inoue H, Hamatani S. Endocytoscopic narrow-band imaging efficiency for evaluation of inflammatory activity in ulcerative colitis. World J Gastroenterol 2015; 21(7): 2108-2115 [PMID: 25717245 DOI: 10.3748/wjg.v21.i7.2108] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
23 Hashash JG, Hartman DJ. Inflammatory cells implicated in neoplasia development in idiopathic inflammatory bowel disease. Cell Immunol 2019;343:103720. [PMID: 29221690 DOI: 10.1016/j.cellimm.2017.11.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Brégeon J, Neunlist M, Bossard C, Biraud M, Coron E, Bourreille A, Meurette G. Improvement of Refractory Ulcerative Proctitis With Sacral Nerve Stimulation. J Clin Gastroenterol 2015;49:853-7. [PMID: 25930972 DOI: 10.1097/MCG.0000000000000331] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
25 Sagami S, Kobayashi T, Aihara K, Umeda M, Morikubo H, Matsubayashi M, Kiyohara H, Nakano M, Ohbu M, Hibi T. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Aliment Pharmacol Ther 2020;51:1373-83. [PMID: 32383166 DOI: 10.1111/apt.15767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
26 Scaioli E, Belluzzi A, Ricciardiello L, Del Rio D, Rotondo E, Mena P, Derlindati E, Danesi F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019;20:327. [PMID: 31171016 DOI: 10.1186/s13063-019-3321-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Pagano E, Romano B, Iannotti F, Parisi O, D’armiento M, Pignatiello S, Coretti L, Lucafò M, Venneri T, Stocco G, Lembo F, Orlando P, Capasso R, Di Marzo V, Izzo A, Borrelli F. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacological Research 2019;149:104464. [DOI: 10.1016/j.phrs.2019.104464] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
28 Sandborn WJ, Peyrin-biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:550-61. [DOI: 10.1053/j.gastro.2019.10.035] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
29 D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2017;46:292-302. [PMID: 28568974 DOI: 10.1111/apt.14164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
30 Ott SJ, Kühbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, Drews O, Weichert W, Timmis KN, Schreiber S. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol. 2008;43:831-841. [PMID: 18584522 DOI: 10.1080/00365520801935434] [Cited by in Crossref: 265] [Cited by in F6Publishing: 245] [Article Influence: 18.9] [Reference Citation Analysis]
31 Klepp P, Kisiel JB, Småstuen MC, Røseth A, Andersen SN, Vatn MH, Ahlquist DA, Moum BA, Brackmann S. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. Scand J Gastroenterol 2018;53:273-8. [PMID: 29313389 DOI: 10.1080/00365521.2018.1424935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Ranson N, Veldhuis M, Mitchell B, Fanning S, Cook AL, Kunde D, Eri R. NLRP3-Dependent and -Independent Processing of Interleukin (IL)-1β in Active Ulcerative Colitis. Int J Mol Sci 2018;20:E57. [PMID: 30583612 DOI: 10.3390/ijms20010057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
33 Gerrits MM, Chen M, Theeuwes M, van Dekken H, Sikkema M, Steyerberg EW, Lingsma HF, Siersema PD, Xia B, Kusters JG. Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol (Dordr). 2011;34:107-117. [PMID: 21327897 DOI: 10.1007/s13402-010-0006-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
34 de Frias Gomes CG, de Almeida ASR, Mendes CCL, Ellul P, Burisch J, Buhagiar T, Attard A, Lo B, Ungaro RC, da Silva Morão BT, Gouveia CF, de Carvalho E Branco JMD, Rodrigues JMMP, Teixeira C, Dias de Castro MFF, Nunes GFD, Brito M, de Sousa Antunes MC, Borralho Nunes PMFB, da Silva Torres JMT. Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis. Inflamm Bowel Dis 2021:izab069. [PMID: 33999195 DOI: 10.1093/ibd/izab069] [Reference Citation Analysis]
35 Brazil JC, Quiros M, Nusrat A, Parkos CA. Innate immune cell-epithelial crosstalk during wound repair. J Clin Invest 2019;129:2983-93. [PMID: 31329162 DOI: 10.1172/JCI124618] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 15.7] [Reference Citation Analysis]
36 Li CQ, Liu J, Ji R, Li Z, Xie XJ, Li YQ. Use of confocal laser endomicroscopy to predict relapse of ulcerative colitis. BMC Gastroenterol. 2014;14:45. [PMID: 24618122 DOI: 10.1186/1471-230x-14-45] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
37 Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M. Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn´s disease. J Crohns Colitis 2021:jjab055. [PMID: 33773497 DOI: 10.1093/ecco-jcc/jjab055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bossard C, Souazé F, Jarry A, Bezieau S, Mosnier JF, Forgez P, Laboisse CL. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis. Peptides 2007;28:2030-5. [PMID: 17870207 DOI: 10.1016/j.peptides.2007.06.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
39 Soendergaard C, Kvist PH, Thygesen P, Reslow M, Nielsen OH, Kopchick JJ, Holm TL. Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. Int J Mol Sci. 2017;18:2046. [PMID: 28946616 DOI: 10.3390/ijms18102046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
40 Takenaka K, Ohtsuka K, Fujii T, Oshima S, Okamoto R, Watanabe M. Deep Neural Network Accurately Predicts Prognosis of Ulcerative Colitis Using Endoscopic Images. Gastroenterology 2021;160:2175-2177.e3. [PMID: 33485853 DOI: 10.1053/j.gastro.2021.01.210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
42 Kim DB, Lee KM, Lee JM, Chung YY, Sung HJ, Paik CN, Chung WC, Jung JH, Choi HJ. Correlation between Histological Activity and Endoscopic, Clinical, and Serologic Activities in Patients with Ulcerative Colitis. Gastroenterol Res Pract 2016;2016:5832051. [PMID: 26839541 DOI: 10.1155/2016/5832051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
43 Li MH, Du HZ, Kong GJ, Liu LB, Li XX, Lin SS, Jia AQ, Yuan ST, Sun L, Wang JS. Nuclear Magnetic Resonance-Based Metabolomics Approach to Evaluate the Prevention Effect of Camellia nitidissima Chi on Colitis-Associated Carcinogenesis. Front Pharmacol 2017;8:447. [PMID: 28744216 DOI: 10.3389/fphar.2017.00447] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
44 Sjöqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Löfberg R. Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 2002;8:258-63. [PMID: 12131609 DOI: 10.1097/00054725-200207000-00004] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
45 Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Hum Pathol. 2012;43:2187-2196. [PMID: 22703923 DOI: 10.1016/j.humpath.2012.03.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
46 Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014; 20(17): 4980-4986 [PMID: 24803809 DOI: 10.3748/wjg.v20.i17.4980] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
47 Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14(1): 53-57 [PMID: 18176961 DOI: 10.3748/wjg.14.53] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
48 Sahn B, De Matos V, Stein R, Ruchelli E, Masur S, Klink AJ, Baldassano RN, Piccoli DA, Russo P, Mamula P. Histological features of ileitis differentiating pediatric Crohn disease from ulcerative colitis with backwash ileitis. Dig Liver Dis 2018;50:147-53. [PMID: 29089273 DOI: 10.1016/j.dld.2017.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
49 Jovanovic M, Simovic Markovic B, Gajovic N, Jurisevic M, Djukic A, Jovanovic I, Arsenijevic N, Lukic A, Zdravkovic N. Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. World J Gastroenterol 2019; 25(43): 6465-6482 [PMID: 31798282 DOI: 10.3748/wjg.v25.i43.6465] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
50 Sargın ZG, Erin N, Tazegul G, Elpek GÖ, Yıldırım B. Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis. PLoS One 2017;12:e0189526. [PMID: 29232715 DOI: 10.1371/journal.pone.0189526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
51 Kovach AE, Moulton DE, Plummer WD Jr, Dupont WD, Pacheco MC. Correlation of Endoscopic and Histologic Severity Scores in Pediatric Ulcerative Colitis at First Presentation. Pediatr Dev Pathol 2019;22:106-11. [PMID: 30301443 DOI: 10.1177/1093526618803736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, Haboubi N, Iovanna JL, Carlson GL, Warhurst G. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(-/-) mice. Inflamm Bowel Dis. 2008;14:620-631. [PMID: 18275070 DOI: 10.1002/ibd.20375] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
53 Saba E, Lee YY, Kim M, Hyun SH, Park CK, Son E, Kim DS, Kim SD, Rhee MH. A novel herbal formulation consisting of red ginseng extract and Epimedium koreanum Nakai-attenuated dextran sulfate sodium-induced colitis in mice. J Ginseng Res 2020;44:833-42. [PMID: 33192127 DOI: 10.1016/j.jgr.2020.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
54 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Reference Citation Analysis]
55 Knyazev OV, Khomeriki SG, Kagramanova АV, Lishchinskaya AA, Smirnova OA, Noskova KK, Parfenov AI. Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. Terapevticheskii arkhiv 2022;93:1435-42. [DOI: 10.26442/00403660.2021.12.201212] [Reference Citation Analysis]
56 Mait-Kaufman J, Fakioglu E, Mesquita PM, Elliott J, Lo Y, Madan RP. Chronic HIV Infection Is Associated with Upregulation of Proinflammatory Cytokine and Chemokine and Alpha Defensin Gene Expression in Colorectal Mucosa. AIDS Res Hum Retroviruses 2015;31:615-22. [PMID: 25768924 DOI: 10.1089/AID.2014.0085] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
57 Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442-450. [PMID: 23461895 DOI: 10.1136/gutjnl-2012-303424] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 10.6] [Reference Citation Analysis]
58 Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A, Merikas EG, Douzinas E, Karagianni M, Sotiriou H. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005; 11(43): 6843-6847 [PMID: 16425394 DOI: 10.3748/wjg.v11.i43.6843] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
59 Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-76. [PMID: 12591057 DOI: 10.1111/j.1572-0241.2003.07239.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
60 Dhingra R, Kedia S, Mouli VP, Garg SK, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Gupta SD, Makharia G, Ahuja V. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission: Predicting relapse in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1698-705. [DOI: 10.1111/jgh.13770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
61 Sznurkowska K, Żawrocki A, Sznurkowski J, Zieliński M, Landowski P, Plata-Nazar K, Iżycka-Świeszewska E, Trzonkowski P, Szlagatys-Sidorkiewicz A, Kamińska B. Peripheral and Intestinal T-regulatory Cells are Upregulated in Children with Inflammatory Bowel Disease at Onset of Disease. Immunol Invest 2016;45:787-96. [PMID: 27759462 DOI: 10.1080/08820139.2016.1214961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
62 Jakubowska K, Pryczynicz A, Iwanowicz P, Niewiński A, Maciorkowska E, Hapanowicz J, Jagodzińska D, Kemona A, Guzińska-Ustymowicz K. Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases. Gastroenterol Res Pract 2016;2016:2456179. [PMID: 27034654 DOI: 10.1155/2016/2456179] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
63 McGillis L, Bronte-Tinkew DM, Dang F, Capurro M, Prashar A, Ricciuto A, Greenfield L, Lozano-Ruf A, Siddiqui I, Hsieh A, Church P, Walters T, Roth DE, Griffiths A, Philpott D, Jones NL. Vitamin D deficiency enhances expression of autophagy-regulating miR-142-3p in mouse and "involved" IBD patient intestinal tissues. Am J Physiol Gastrointest Liver Physiol 2021;321:G171-84. [PMID: 34159811 DOI: 10.1152/ajpgi.00398.2020] [Reference Citation Analysis]
64 González-Bernardo O, Riestra S, Vivas S, de Francisco R, Pérez-Martínez I, Castaño-García A, Jiménez-Beltrán V, Rollé V, Suárez P, Suárez A. Chromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study. Inflamm Bowel Dis 2021;27:1256-62. [PMID: 33169787 DOI: 10.1093/ibd/izaa291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Shi Y, He W, Zhong M, Yu M. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases. Genomics 2021;113:1988-98. [PMID: 33872704 DOI: 10.1016/j.ygeno.2021.04.011] [Reference Citation Analysis]
66 Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology 2020;159:2052-64. [PMID: 32853634 DOI: 10.1053/j.gastro.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
67 Korelitz BI. Mucosal healing as an index of colitis activity: Back to histological healing for future indices: . Inflammatory Bowel Diseases 2010;16:1628-30. [DOI: 10.1002/ibd.21268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
68 Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, Vanuytsel T. Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? Front Immunol 2021;12:754413. [PMID: 34737752 DOI: 10.3389/fimmu.2021.754413] [Reference Citation Analysis]
69 Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol 2017; 15: 1557-1564. e1. [PMID: 28238954 DOI: 10.1016/j.cgh.2017.02.016] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 19.0] [Reference Citation Analysis]
70 Münch A, Söderholm JD, Ost A, Ström M. Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment. Am J Gastroenterol. 2009;104:679-685. [PMID: 19209166 DOI: 10.1038/ajg.2008.95] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
71 Walker MM, Potter MD, Talley NJ. Eosinophilic colitis and colonic eosinophilia. Curr Opin Gastroenterol 2019;35:42-50. [PMID: 30480590 DOI: 10.1097/MOG.0000000000000492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Ghosh A, Saha DR, Hoque KM, Asakuna M, Yamasaki S, Koley H, Das SS, Chakrabarti MK, Pal A. Enterotoxigenicity of mature 45-kilodalton and processed 35-kilodalton forms of hemagglutinin protease purified from a cholera toxin gene-negative Vibrio cholerae non-O1, non-O139 strain. Infect Immun 2006;74:2937-46. [PMID: 16622232 DOI: 10.1128/IAI.74.5.2937-2946.2006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
73 Sahami S, Wildenberg ME, Koens L, Doherty G, Martin S, D'Haens GRAM, Cullen G, Bemelman WA, Winter D, Buskens CJ. Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study. J Crohns Colitis 2019;13:165-71. [PMID: 30285094 DOI: 10.1093/ecco-jcc/jjy127] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
74 Feakins RM; British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol. 2013;66:1005-1026. [PMID: 23999270 DOI: 10.1136/jclinpath-2013-201885] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 11.2] [Reference Citation Analysis]
75 McGowan I, Elliott J, Cortina G, Tanner K, Siboliban C, Adler A, Cho D, Boscardin WJ, Soto-Torres L, Anton PA. Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr 2007;46:417-25. [PMID: 17891044 DOI: 10.1097/QAI.0b013e318156ef16] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
76 Deng F, Peng L, Li Z, Tan G, Liang E, Chen S, Zhao X, Zhi F. YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury. Cell Death Dis 2018;9:153. [PMID: 29396428 DOI: 10.1038/s41419-017-0244-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
77 Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, Ferrante M. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. United European Gastroenterol J 2018;6:765-72. [PMID: 30083339 DOI: 10.1177/2050640617752207] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
78 Magro F, Lopes J, Borralho P, Dias CC, Afonso J, Ministro P, Santiago M, Geboes K, Carneiro F; Portuguese IBD Study Group [GEDII] . Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. J Crohns Colitis 2020;14:1021-5. [PMID: 31965158 DOI: 10.1093/ecco-jcc/jjaa010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
79 Tye H, Yu CH, Simms LA, de Zoete MR, Kim ML, Zakrzewski M, Penington JS, Harapas CR, Souza-Fonseca-Guimaraes F, Wockner LF, Preaudet A, Mielke LA, Wilcox SA, Ogura Y, Corr SC, Kanojia K, Kouremenos KA, De Souza DP, McConville MJ, Flavell RA, Gerlic M, Kile BT, Papenfuss AT, Putoczki TL, Radford-Smith GL, Masters SL. NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease. Nat Commun 2018;9:3728. [PMID: 30214011 DOI: 10.1038/s41467-018-06125-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
80 Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-36. e1. [PMID: 26051392 DOI: 10.1016/j.cgh.2015.05.038] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
81 Garrity-Park M, Loftus EV Jr, Sandborn WJ, Smyrk TC. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis 2012;18:275-83. [PMID: 21425209 DOI: 10.1002/ibd.21681] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
82 Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-105; quiz 1340. [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001] [Cited by in Crossref: 489] [Cited by in F6Publishing: 422] [Article Influence: 32.6] [Reference Citation Analysis]
83 Sena AA, Pedrotti LP, Barrios BE, Cejas H, Balderramo D, Diller A, Correa SG. Lack of TNFRI signaling enhances annexin A1 biological activity in intestinal inflammation. Biochem Pharmacol 2015;98:422-31. [PMID: 26386311 DOI: 10.1016/j.bcp.2015.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
84 Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, Sanjuan X, Sánchez E, Rodríguez-Moranta F. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12:1865-1870. [PMID: 24993368 DOI: 10.1016/j.cgh.2014.06.020] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
85 Polese L, Boetto R, De Franchis G, Angriman I, Porzionato A, Norberto L, Sturniolo GC, Macchi V, De Caro R, Merigliano S. B1a lymphocytes in the rectal mucosa of ulcerative colitis patients. World J Gastroenterol 2012; 18(2): 144-149 [PMID: 22253520 DOI: 10.3748/wjg.v18.i2.144] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
86 van der Sluis WB, Neefjes-borst EA, Bouman M, Meijerink WJHJ, De Boer NKH, Mullender MG, van Bodegraven AA. Morphological spectrum of neovaginitis in autologous sigmoid transplant patients. Histopathology 2016;68:1004-12. [DOI: 10.1111/his.12894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
87 Lamet M, Ptak T, Dallaire C, Shah U, Grace M, Spenard J, de Montigny D. Efficacy and Safety of Mesalamine 1 g HS Versus 500 mg BID Suppositories in Mild to Moderate Ulcerative Proctitis: A Multicenter Randomized Study: . Inflammatory Bowel Diseases 2005;11:625-30. [DOI: 10.1097/01.mib.0000171277.70404.40] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
88 Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
89 Fabian O, Hradsky O, Potuznikova K, Kalfusova A, Krskova L, Hornofova L, Zamecnik J, Bronsky J. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathology - Research and Practice 2017;213:353-8. [DOI: 10.1016/j.prp.2017.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
90 Fron C, Pierry C, Poullenot F, Chabrun E, Subtil C, Capdepont M, Zerbib F, Belleannée G, Laharie D. Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. Dig Liver Dis 2016;48:734-9. [PMID: 27052254 DOI: 10.1016/j.dld.2016.03.007] [Reference Citation Analysis]
91 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
92 Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011;17:194-198. [PMID: 21546723 DOI: 10.4103/1319-3767.80383] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
93 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
94 Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis. 2017;11:84-91. [PMID: 27466171 DOI: 10.1093/ecco-jcc/jjw132] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
95 Farkas K, Saródi Z, Bálint A, Földesi I, Tiszlavicz L, Szűcs M, Nyári T, Tajti J, Nagy F, Szepes Z, Bor R, Annaházi A, Róka R, Molnár T. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. J Crohns Colitis 2015;9:231-7. [PMID: 25585596 DOI: 10.1093/ecco-jcc/jjv005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
96 Buanne P, Di Carlo E, Caputi L, Brandolini L, Mosca M, Cattani F, Pellegrini L, Biordi L, Coletti G, Sorrentino C. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol. 2007;82:1239-1246. [PMID: 17656654 DOI: 10.1189/jlb.0207118] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 4.5] [Reference Citation Analysis]
97 Walter SA, Münch A, Ost A, Ström M. Anorectal function in patients with collagenous colitis in active and clinically quiescent phase, in comparison with healthy controls. Neurogastroenterol Motil 2010;22:534-8, e118. [PMID: 20156310 DOI: 10.1111/j.1365-2982.2010.01472.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Kevans D, Kirsch R, Dargavel C, Kabakchiev B, Riddell R, Silverberg MS. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. Inflamm Bowel Dis. 2020;26:1722-1729. [PMID: 31883337 DOI: 10.1093/ibd/izz308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
99 Kelsen JR, Dawany N, Conrad MA, Karakasheva TA, Maurer K, Wei JM, Uman S, Dent MH, Behera R, Bryant LM, Ma X, Moreira L, Chatterji P, Shraim R, Merz A, Mizuno R, Simon LA, Muir AB, Giraudo C, Behrens EM, Whelan KA, Devoto M, Russo PA, Andres SF, Sullivan KE, Hamilton KE. Colonoids From Patients With Pediatric Inflammatory Bowel Disease Exhibit Decreased Growth Associated With Inflammation Severity and Durable Upregulation of Antigen Presentation Genes. Inflamm Bowel Dis 2021;27:256-67. [PMID: 32556182 DOI: 10.1093/ibd/izaa145] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Kaur S, Singh K. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol. 2009;24:1768-1774. [PMID: 20136960 DOI: 10.1111/j.1440-1746.2009.06048.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
101 Tartakover Matalon S, Ringel Y, Konikoff F, Drucker L, Pery S, Naftali T. Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. United European Gastroenterol J 2020;8:271-83. [PMID: 32213014 DOI: 10.1177/2050640619889773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
103 Iacucci M, Panaccione R. Recent advances in the endoscopic assessment of ulcerative colitis. Techniques in Gastrointestinal Endoscopy 2016;18:116-22. [DOI: 10.1016/j.tgie.2016.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
104 Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 2016;44:157-69. [PMID: 27218676 DOI: 10.1111/apt.13653] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
105 Lavelle A, Lennon G, O'Sullivan O, Docherty N, Balfe A, Maguire A, Mulcahy HE, Doherty G, O'Donoghue D, Hyland J, Ross RP, Coffey JC, Sheahan K, Cotter PD, Shanahan F, Winter DC, O'Connell PR. Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. Gut. 2015;64:1553-1561. [PMID: 25596182 DOI: 10.1136/gutjnl-2014-307873] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 18.9] [Reference Citation Analysis]
106 Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. J Crohns Colitis 2021;15:551-66. [PMID: 32898223 DOI: 10.1093/ecco-jcc/jjaa176] [Reference Citation Analysis]
107 Uchida K, Koike Y, Hashimoto K, Saigusa S, Inoue M, Otake K, Tanaka K, Matsushita K, Okita Y, Fujikawa H, Araki T, Mohri Y, Kusunoki M. The Increased Expression of CCL20 and CCR6 in Rectal Mucosa Correlated to Severe Inflammation in Pediatric Ulcerative Colitis. Gastroenterol Res Pract 2015;2015:856532. [PMID: 25691899 DOI: 10.1155/2015/856532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
108 Jauregui-Amezaga A, Geerits A, Das Y, Lemmens B, Sagaert X, Bessissow T, Lobatón T, Ferrante M, Van Assche G, Bisschops R, Geboes K, De Hertogh G, Vermeire S. A Simplified Geboes Score for Ulcerative Colitis. J Crohns Colitis 2017;11:305-13. [PMID: 27571771 DOI: 10.1093/ecco-jcc/jjw154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
109 Takishima K, Maeda Y, Ogata N, Misawa M, Mori Y, Homma M, Nemoto T, Miyata Y, Akimoto Y, Mochida K, Takashina Y, Tanaka K, Ichimasa K, Nakamura H, Sasanuma S, Kudo T, Hayashi T, Wakamura K, Miyachi H, Baba T, Ishida F, Ohtsuka K, Kudo SE. Beyond complete endoscopic healing: Goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. Dig Endosc 2021. [PMID: 34816494 DOI: 10.1111/den.14202] [Reference Citation Analysis]
110 Gironella M, Iovanna JL, Sans M, Gil F, Peñalva M, Closa D, Miquel R, Piqué JM, Panés J. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 2005;54:1244-53. [PMID: 15870231 DOI: 10.1136/gut.2004.056309] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
111 Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78:532-41. [PMID: 32931028 DOI: 10.1111/his.14248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Naganuma M, Yahagi N, Bessho R, Ohno K, Arai M, Mutaguchi M, Mizuno S, Fujimoto A, Uraoka T, Shimoda M, Hosoe N, Ogata H, Kanai T. Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open 2017;5:E76-82. [PMID: 28180151 DOI: 10.1055/s-0042-119393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
113 Gruver AM, Westfall MD, Ackermann BL, Hill S, Morrison RD, Bodo J, Lai KK, Gemperline DC, Hsi ED, Liebler DC, Schmitz J, Benschop RJ. Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. J Clin Pathol 2021:jclinpath-2021-207718. [PMID: 34353876 DOI: 10.1136/jclinpath-2021-207718] [Reference Citation Analysis]
114 Casellas F, Borruel N, Antolín M, Varela E, Torrejón A, Armadans L, Guarner F, Malagelada JR. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis. 2007;13:386-390. [PMID: 17206700 DOI: 10.1002/ibd.20042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
115 Fernández-blanco JI, Fernández-díaz G, Cara C, Vera MI, Olivares D, Taxonera C. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. Dig Dis Sci 2018;63:731-7. [DOI: 10.1007/s10620-018-4935-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
116 Abreu MT, Sandborn WJ; IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology 2020;159:2013-2018.e7. [PMID: 32961246 DOI: 10.1053/j.gastro.2020.07.064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Eckmann L, Kagnoff MF. Intestinal mucosal responses to microbial infection. Springer Semin Immunopathol 2005;27:181-96. [PMID: 15928914 DOI: 10.1007/s00281-005-0207-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
118 Chang J, Adams MR, Clifton MS, Liao M, Brooks JH, Hasdemir B, Bhargava A. Urocortin 1 modulates immunosignaling in a rat model of colitis via corticotropin-releasing factor receptor 2. Am J Physiol Gastrointest Liver Physiol. 2011;300:G884-G894. [PMID: 21330446 DOI: 10.1152/ajpgi.00319.2010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
119 Mosli MH, Parker CE, Nelson SA, Baker KA, MacDonald JK, Zou GY, Feagan BG, Khanna R, Levesque BG, Jairath V. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2017;5:CD011256. [PMID: 28542712 DOI: 10.1002/14651858.CD011256.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
120 Marchal Bressenot A. Which evidence for a treat to target strategy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:3-8. [DOI: 10.1016/j.bpg.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
121 Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointestinal Endoscopy 2018;88:887-98. [DOI: 10.1016/j.gie.2018.08.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
122 Honzawa Y, Matsuura M, Higuchi H, Sakurai T, Seno H, Nakase H. A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis. Endosc Int Open 2020;8:E41-9. [PMID: 31921983 DOI: 10.1055/a-0990-9375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 Abreu-Delgado Y, Isidro RA, Torres EA, González A, Cruz ML, Isidro AA, González-Keelan CI, Medero P, Appleyard CB. Serum vitamin D and colonic vitamin D receptor in inflammatory bowel disease. World J Gastroenterol 2016; 22(13): 3581-3591 [PMID: 27053850 DOI: 10.3748/wjg.v22.i13.3581] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
124 Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 126] [Cited by in F6Publishing: 119] [Article Influence: 8.4] [Reference Citation Analysis]
125 Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. Reproducibility of histological assessments of disease activity in UC. Gut 2015;64:1765-73. [DOI: 10.1136/gutjnl-2014-307536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
126 Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut 2017;66:2063-8. [PMID: 27590995 DOI: 10.1136/gutjnl-2016-312307] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
127 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis. 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
129 Abdelrazeq AS, Wilson TR, Leitch DL, Lund JN, Leveson SH. Ileitis in ulcerative colitis: is it a backwash? Dis Colon Rectum. 2005;48:2038-2046. [PMID: 16175321 DOI: 10.1007/s10350-005-0160-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
130 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
131 Qian WH, Liu YY, Li X, Pan Y. MicroRNA-141 ameliorates alcoholic hepatitis‑induced intestinal injury and intestinal endotoxemia partially via a TLR4-dependent mechanism. Int J Mol Med 2019;44:569-81. [PMID: 31173169 DOI: 10.3892/ijmm.2019.4221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Villanacci V, Reggiani-Bonetti L, Caprioli F, Saragoni L, Salviato T, Mescoli C, Canavese G, Manenti S, Spada E, Baron L, Leoncini G, Cadei M, Battista S, Armuzzi A. Histopathology of inflammatory bowel disease - Position statement of the Pathologists of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Group of Gastrointestinal Pathologists (GIPAD-SIAPEC). Dig Liver Dis 2020;52:262-7. [PMID: 31884010 DOI: 10.1016/j.dld.2019.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
133 Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2018;16:1268-1275.e2. [PMID: 29391271 DOI: 10.1016/j.cgh.2018.01.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
134 Gioxari A, Kaliora AC, Papalois A, Agrogiannis G, Triantafillidis JK, Andrikopoulos NK. Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis. J Med Food 2011;14:1403-11. [PMID: 21612460 DOI: 10.1089/jmf.2010.0240] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
135 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Shi HY, Chan FKL, Chan AWH, Higashimori A, Kyaw M, Ching JYL, Luk AKC, Wong SH, Wu JCY, Sung JJY, Ng SC. Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. Journal of Crohn's and Colitis 2017;11:1071-7. [DOI: 10.1093/ecco-jcc/jjx088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
137 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
138 Catinean A, Neag MA, Krishnan K, Muntean DM, Bocsan CI, Pop RM, Mitre AO, Melincovici CS, Buzoianu AD. Probiotic Bacillus Spores Together with Amino Acids and Immunoglobulins Exert Protective Effects on a Rat Model of Ulcerative Colitis. Nutrients 2020;12:E3607. [PMID: 33255321 DOI: 10.3390/nu12123607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Macé V, Ahluwalia A, Coron E, Le Rhun M, Boureille A, Bossard C, Mosnier JF, Matysiak-Budnik T, Tarnawski AS. Confocal laser endomicroscopy: a new gold standard for the assessment of mucosal healing in ulcerative colitis. J Gastroenterol Hepatol. 2015;30 Suppl 1:85-92. [PMID: 25827810 DOI: 10.1111/jgh.12748] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
140 Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005;11:488-96. [PMID: 15867589 DOI: 10.1097/01.mib.0000159661.55028.56] [Cited by in Crossref: 183] [Cited by in F6Publishing: 60] [Article Influence: 10.8] [Reference Citation Analysis]
141 Gubatan J, Mitsuhashi S, Longhi MS, Zenlea T, Rosenberg L, Robson S, Moss AC. Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine. 2018;103:38-45. [PMID: 29324259 DOI: 10.1016/j.cyto.2017.12.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
142 Almradi A, Ma C, D'haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36. [PMID: 17784949 DOI: 10.1186/1471-230x-7-36] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
144 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Sousa HT, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Cornillie F, Lopes J, Carneiro F; Portuguese IBD Group [GEDII]. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. Journal of Crohn's and Colitis 2019;13:1387-93. [DOI: 10.1093/ecco-jcc/jjz071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
145 Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology 2017; 153: 723-731. e1. [PMID: 28601482 DOI: 10.1053/j.gastro.2017.05.056] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 18.4] [Reference Citation Analysis]
146 Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42. [PMID: 21997563 DOI: 10.1136/gutjnl-2011-300486] [Cited by in Crossref: 295] [Cited by in F6Publishing: 254] [Article Influence: 26.8] [Reference Citation Analysis]
147 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
148 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Eberhardson M, Finkel Y. Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis. J Pediatr Gastroenterol Nutr 2018;66:e103-7. [PMID: 28891831 DOI: 10.1097/MPG.0000000000001735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
150 Bossuyt P, Bisschops R, Vermeire S, De Hertogh G. Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis. J Crohns Colitis 2021;15:603-8. [PMID: 33053161 DOI: 10.1093/ecco-jcc/jjaa206] [Reference Citation Analysis]
151 Saba E, Lee YY, Rhee MH, Kim SD. Alleviation of Ulcerative Colitis Potentially through th1/th2 Cytokine Balance by a Mixture of Rg3-enriched Korean Red Ginseng Extract and Persicaria tinctoria. Molecules 2020;25:E5230. [PMID: 33182623 DOI: 10.3390/molecules25225230] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Onwuka E, Huntington J, Onwuka A, Prasad V, Nwomeh B. Acute histologic inflammatory activity and postoperative outcomes in pediatric patients with ulcerative colitis. Am J Surg 2020;219:592-7. [PMID: 32209240 DOI: 10.1016/j.amjsurg.2020.02.054] [Reference Citation Analysis]
153 Hilpüsch F, Johnsen PH, Goll R, Valle PC, Sørbye SW, Abelsen B. Microscopic colitis: a missed diagnosis among patients with moderate to severe irritable bowel syndrome. Scandinavian Journal of Gastroenterology 2017;52:173-7. [DOI: 10.1080/00365521.2016.1242025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
154 Sham HP, Bazett M, Bosiljcic M, Yang H, Luk B, Law HT, Morampudi V, Yu HB, Pankovich J, Sutcliffe S, Bressler B, Marshall JK, Fedorak RN, Chen J, Jones M, Gunn H, Kalyan S, Vallance BA. Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Front Immunol 2018;9:2211. [PMID: 30319652 DOI: 10.3389/fimmu.2018.02211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
155 Ricciuto A, Hansen BE, Ngo B, Aloi M, Walters TD, Church PC, Mazurek A, Khan M, Carman N, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM. Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clinical Gastroenterology and Hepatology 2020;18:1509-1517.e7. [DOI: 10.1016/j.cgh.2019.08.048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
156 Mirza AH, Berthelsen CH, Seemann SE, Pan X, Frederiksen KS, Vilien M, Gorodkin J, Pociot F. Transcriptomic landscape of lncRNAs in inflammatory bowel disease. Genome Med. 2015;7:39. [PMID: 25991924 DOI: 10.1186/s13073-015-0162-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 13.9] [Reference Citation Analysis]
157 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
158 Kotlo K, Anbazhagan AN, Priyamvada S, Jayawardena D, Kumar A, Chen Y, Xia Y, Finn PW, Perkins DL, Dudeja PK, Layden BT. The olfactory G protein-coupled receptor (Olfr-78/OR51E2) modulates the intestinal response to colitis. Am J Physiol Cell Physiol 2020;318:C502-13. [PMID: 31913697 DOI: 10.1152/ajpcell.00454.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
159 Kelm M, Lehoux S, Azcutia V, Cummings RD, Nusrat A, Parkos CA, Brazil JC. Regulation of neutrophil function by selective targeting of glycan epitopes expressed on the integrin CD11b/CD18. FASEB J 2020;34:2326-43. [PMID: 31907993 DOI: 10.1096/fj.201902542R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
160 Abou El Azm AR, Yousef M, Kobtan A, Awad A, Elkassas G, Elfert A. Colonic mucosal expression of heat-shock proteins may have a potential prognostic value in ulcerative colitis. Arab J Gastroenterol 2015;16:20-4. [PMID: 25797489 DOI: 10.1016/j.ajg.2015.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
161 Shah J, Dutta U, Das A, Sharma V, Mandavdhare H, Sharma P, Kalsi D, Popli P, Kochhar R. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open 2020;4:382-6. [PMID: 32514441 DOI: 10.1002/jgh3.12260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Neri B, Mossa M, Scucchi L, Sena G, Palmieri G, Biancone L. Histological scores in inflammatory bowel disease. J Dig Dis 2021;22:9-22. [PMID: 32897005 DOI: 10.1111/1751-2980.12937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
163 Tursi A, Elisei W, Picchio M, Brandimarte G. Histological inflammation in Crohn's disease in deep remission during treatment with anti-TNFα. Digestive and Liver Disease 2014;46:575-6. [DOI: 10.1016/j.dld.2014.01.161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Pai RK, Hartman DJ, Rivers CR, Regueiro M, Schwartz M, Binion DG, Pai RK. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2510-2517.e5. [DOI: 10.1016/j.cgh.2019.12.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
165 Podgórska J, Pasicz K, Zagórowicz E, Mróz A, Gołębiewski B, Kuś P, Jasieniak J, Skrzyński W, Wieszczy P, Kukołowicz P, Cieszanowski A. Intravoxel incoherent motion MRI in evaluating inflammatory activity in ulcerative colitis: a pilot study. Acta Radiol 2021;62:439-46. [PMID: 32536258 DOI: 10.1177/0284185120931689] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Wejman J, Pyzlak M, Szukiewicz D, Jarosz D, Tarnowski W, Szewczyk G. Thrombospondin and VEGF-R: is there a correlation in inflammatory bowel disease? Mediators Inflamm 2013;2013:908259. [PMID: 23970816 DOI: 10.1155/2013/908259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
167 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 820] [Article Influence: 133.9] [Reference Citation Analysis]
168 De Preter V, Geboes KP, Bulteel V, Vandermeulen G, Suenaert P, Rutgeerts P, Verbeke K. Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β-oxidation pathway. Aliment Pharmacol Ther 2011;34:526-32. [PMID: 21707682 DOI: 10.1111/j.1365-2036.2011.04757.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
169 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
170 Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs 2021;81:985-1002. [PMID: 33983615 DOI: 10.1007/s40265-021-01528-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
171 Fenton CG, Taman H, Florholmen J, Sørbye SW, Paulssen RH. Transcriptional Signatures That Define Ulcerative Colitis in Remission. Inflamm Bowel Dis 2021;27:94-105. [PMID: 32322884 DOI: 10.1093/ibd/izaa075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
172 Harding SV, Fraser KG, Wykes LJ. Probiotics stimulate liver and plasma protein synthesis in piglets with dextran sulfate-induced colitis and macronutrient restriction. J Nutr 2008;138:2129-35. [PMID: 18936209 DOI: 10.3945/jn.108.090019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
173 Li CQ, Xie XJ, Yu T, Gu XM, Zuo XL, Zhou CJ, Huang WQ, Chen H, Li YQ. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol. 2010;105:1391-1396. [PMID: 19935787 DOI: 10.1038/ajg.2009.664] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
174 Buda A, Hatem G, Neumann H, D' Incà R, Mescoli C, Piselli P, Jackson J, Bruno M, Sturniolo GC. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. Journal of Crohn's and Colitis 2014;8:304-11. [DOI: 10.1016/j.crohns.2013.09.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
175 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
176 Brandse JF, Bennink RJ, van Eeden S, Löwenberg M, van den Brink GR, DʼHaens GR. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1384-90. [PMID: 26978724 DOI: 10.1097/MIB.0000000000000746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9:50-55. [PMID: 25518048 DOI: 10.1093/ecco-jcc/jju003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 10.0] [Reference Citation Analysis]
178 Román J, Planell N, Lozano JJ, Aceituno M, Esteller M, Pontes C, Balsa D, Merlos M, Panés J, Salas A. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis 2013;19:221-9. [PMID: 22605655 DOI: 10.1002/ibd.23020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
179 Dotan I, Levy-Nissenbaum E, Chowers Y, Fich A, Israeli E, Adar T, Shteingart S, Soreq H, Goldin E. Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. Dig Dis Sci 2016;61:3246-54. [PMID: 27572942 DOI: 10.1007/s10620-016-4276-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
180 Pedrotti LP, Sena AA, Rodriguez Galán MC, Cejas H, Correa SG. Intestinal mononuclear cells primed by systemic interleukin-12 display long-term ability to aggravate colitis in mice. Immunology 2017;150:290-300. [PMID: 27891587 DOI: 10.1111/imm.12685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
181 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020;51:689-698. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
182 Block M, Jørgensen KK, Oresland T, Lindholm E, Grzyb K, Cvancarova M, Vatn MH, Boberg KM, Börjesson L. Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis - what next? J Crohns Colitis. 2014;8:421-430. [PMID: 24239402 DOI: 10.1016/j.crohns.2013.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
183 Geboes K. Pathology of inflammatory bowel diseases (IBD): variability with time and treatment. Colorect Dis 2001;3:2-12. [DOI: 10.1046/j.1463-1318.2001.00187.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
184 Hundorfean G, Chiriac MT, Mihai S, Hartmann A, Mudter J, Neurath MF. Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflamm Bowel Dis 2017;24:35-44. [PMID: 29272480 DOI: 10.1093/ibd/izx012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
185 Brown IS, Liu C, Miller GC. Sampling and Reporting of Inflammatory Bowel Disease. Adv Anat Pathol 2022;29:25-36. [PMID: 34879036 DOI: 10.1097/PAP.0000000000000318] [Reference Citation Analysis]
186 Lennon G, Balfe Á, Bambury N, Lavelle A, Maguire A, Docherty NG, Coffey JC, Winter DC, Sheahan K, O'Connell PR. Correlations between colonic crypt mucin chemotype, inflammatory grade and Desulfovibrio species in ulcerative colitis. Colorectal Dis 2014;16:O161-9. [PMID: 24345279 DOI: 10.1111/codi.12503] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
187 Milkiewicz M, Klak M, Kempinska-Podhorodecka A, Wiechowska-Kozlowska A, Urasinska E, Blatkiewicz M, Wunsch E, Elias E, Milkiewicz P. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis. Sci Rep 2016;6:39573. [PMID: 28008998 DOI: 10.1038/srep39573] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
188 Yeung CC, Hockenbery DM, Westerhoff M, Coutre SE, Sedlak RH, Dubowy RL, Munugalavadla V, Taylor K, Bosch F. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. Future Oncol 2018;14:2265-77. [PMID: 29569483 DOI: 10.2217/fon-2017-0528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
189 Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: A still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978 [PMID: 23467585 DOI: 10.3748/wjg.v19.i7.968] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
190 Earley H, Lennon G, Balfe A, Kilcoyne M, Clyne M, Joshi L, Carrington S, Martin ST, Coffey JC, Winter DC, O'Connell PR. A Preliminary Study Examining the Binding Capacity of Akkermansia muciniphila and Desulfovibrio spp., to Colonic Mucin in Health and Ulcerative Colitis. PLoS One 2015;10:e0135280. [PMID: 26491870 DOI: 10.1371/journal.pone.0135280] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
191 Kaenkumchorn T, Wahbeh G. Ulcerative Colitis: Making the Diagnosis. Gastroenterol Clin North Am 2020;49:655-69. [PMID: 33121687 DOI: 10.1016/j.gtc.2020.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Stevens TW, Gecse K, Turner JR, de Hertogh G, Rubin DT, D'Haens GR. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31128-9. [PMID: 32801008 DOI: 10.1016/j.cgh.2020.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
193 Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Andrade P, Soares JB, Carvalho D, Sousa P, Meira T, Lopes J, Moleiro J, Dias CC, Falcão A, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. EBioMedicine 2017;21:123-30. [PMID: 28629912 DOI: 10.1016/j.ebiom.2017.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Muratov V, Lundahl J, Mandic-havelka A, Elvin K, Öst Å, Shizume Y, Furuya K, Löfberg R. Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study. J Clin Apheresis 2010;25:287-93. [DOI: 10.1002/jca.20255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
195 Ippolito C, Colucci R, Segnani C, Errede M, Girolamo F, Virgintino D, Dolfi A, Tirotta E, Buccianti P, Di Candio G, Campani D, Castagna M, Bassotti G, Villanacci V, Blandizzi C, Bernardini N. Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis. J Crohns Colitis 2016;10:1194-204. [PMID: 26995183 DOI: 10.1093/ecco-jcc/jjw076] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
196 De Vries LCS, Ludbrook VJ, Hicks KJ, D'Haens GR. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. BMJ Case Rep 2017;2017:bcr-2017-221078. [PMID: 28790099 DOI: 10.1136/bcr-2017-221078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
197 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
198 da Rocha GHO, de Paula-Silva M, Broering MF, Scharf PRDS, Matsuyama LSAS, Maria-Engler SS, Farsky SHP. Pioglitazone-Mediated Attenuation of Experimental Colitis Relies on Cleaving of Annexin A1 Released by Macrophages. Front Pharmacol 2020;11:591561. [PMID: 33519451 DOI: 10.3389/fphar.2020.591561] [Reference Citation Analysis]
199 Vinayaga-Pavan M, Frampton M, Pontikos N, Levine AP, Smith PJ, Jonasson JG, Björnsson ES, Segal AW, Smith AM. Elevation in Cell Cycle and Protein Metabolism Gene Transcription in Inactive Colonic Tissue From Icelandic Patients With Ulcerative Colitis. Inflamm Bowel Dis 2019;25:317-27. [PMID: 30452647 DOI: 10.1093/ibd/izy350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
200 Rath T, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? Expert Rev Gastroenterol Hepatol 2021;15:665-74. [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892] [Reference Citation Analysis]
201 Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, Nelson AJ, Worthley SG, Abhayaratna WP, Kalman JM, Wittert GA, Sanders P. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm 2013;10:90-100. [DOI: 10.1016/j.hrthm.2012.08.043] [Cited by in Crossref: 215] [Cited by in F6Publishing: 190] [Article Influence: 23.9] [Reference Citation Analysis]
202 Schuster AT, Homer CR, Kemp JR, Nickerson KP, Deutschman E, Kim Y, West G, Sadler T, Stylianou E, Krokowski D, Hatzoglou M, de la Motte C, Rubin BP, Fiocchi C, McDonald C, Longworth MS. Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters. Gastroenterology. 2015;148:1405-1416.e3. [PMID: 25701737 DOI: 10.1053/j.gastro.2015.02.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
203 Rasmussen DN, Karstensen JG, Riis LB, Brynskov J, Vilmann P. Confocal Laser Endomicroscopy in Inflammatory Bowel Disease--A Systematic Review. J Crohns Colitis. 2015;9:1152-1159. [PMID: 26209861 DOI: 10.1093/ecco-jcc/jjv131] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
204 Jain D, Warren BF, Riddell RH. Inflammatory Disorders of the Large Intestine. In: Shepherd NA, Warren BF, Williams GT, Greenson JK, Lauwers GY, Novelli MR, editors. Morson and Dawson's Gastrointestinal Pathology. Oxford: Wiley-Blackwell; 2013. pp. 552-635. [DOI: 10.1002/9781118399668.ch35] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
205 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 31.0] [Reference Citation Analysis]
206 Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL. Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. Journal of Crohn's and Colitis 2018;12:1151-7. [DOI: 10.1093/ecco-jcc/jjy081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
207 Gordon IO, Agrawal N, Willis E, Goldblum JR, Lopez R, Allende D, Liu X, Patil DY, Yerian L, El-Khider F, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther 2018;47:922-39. [PMID: 29411405 DOI: 10.1111/apt.14526] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
208 Zhou Q, Ma L, Zhao W, Zhao W, Han X, Niu J, Li R, Zhao C. Flaxseed oil alleviates dextran sulphate sodium-induced ulcerative colitis in rats. Journal of Functional Foods 2020;64:103602. [DOI: 10.1016/j.jff.2019.103602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
209 Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-60. [PMID: 24039442 DOI: 10.2147/CEG.S35163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
210 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 20.3] [Reference Citation Analysis]
211 Guardiola J, Arajol C, Armuzzi A. Is histologic remission in ulcerative colitis ready for prime time? Digestive and Liver Disease 2017;49:1334-5. [DOI: 10.1016/j.dld.2017.09.130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
212 Karstensen JG, Săftoiu A, Brynskov J, Hendel J, Ciocalteu A, Klausen P, Klausen TW, Riis LB, Vilmann P. Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). Gastrointest Endosc 2016;84:279-286.e1. [PMID: 26945556 DOI: 10.1016/j.gie.2016.01.069] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
213 Papalois AE, Barbatis C, Chrysikos D, Korontzi M, Sideris M, Pittaras T, Triantafyllidi E, Nomikos A, Triantafillidis JK. Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats. Biomed Res Int 2019;2019:8298192. [PMID: 31687401 DOI: 10.1155/2019/8298192] [Reference Citation Analysis]
214 Arlander E, Löfberg R, Törkvist L, Lindforss U. Exploring anorectal manometry as a method to study the effect of locally administered ropivacaine in patients with ulcerative colitis. ISRN Gastroenterol. 2013;2013:656921. [PMID: 23476794 DOI: 10.1155/2013/656921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
215 Yamamoto-Furusho JK, Martínez-Benítez B, Sánchez-Morales GE. Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. Gastroenterol Res Pract 2020;2020:8891937. [PMID: 33343656 DOI: 10.1155/2020/8891937] [Reference Citation Analysis]
216 Margonis GA, Christoloukas N, Antoniou E, Arkadopoulos N, Theodoropoulos G, Agrogiannis G, Pikoulis E, Patsouris ES, Zografos GC, Papalois AE. Effectiveness of sildenafil and U-74389G in a rat model of colitis. J Surg Res 2015;193:667-74. [PMID: 25277360 DOI: 10.1016/j.jss.2014.08.064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
217 Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. Disease Activity Indices for Pouchitis: A Systematic Review. Inflamm Bowel Dis 2021:izab124. [PMID: 34180986 DOI: 10.1093/ibd/izab124] [Reference Citation Analysis]
218 Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?: . Inflammatory Bowel Diseases 2012;18:2056-62. [DOI: 10.1002/ibd.22879] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
219 Gawad N, El Demellawy D, Wayne C, Bass J, Nasr A. Histologic inflammatory activity of the rectal margin as a predictor of postoperative complication in ileoanal anastomosis (J-pouch) procedure in children with refractory ulcerative colitis. J Pediatr Surg 2016;51:783-5. [PMID: 26921936 DOI: 10.1016/j.jpedsurg.2016.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
220 Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, Danese S, Villanacci V, Feakins R. ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. J Crohns Colitis 2020;14:1503-11. [PMID: 32504534 DOI: 10.1093/ecco-jcc/jjaa110] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
221 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
222 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372-84. [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
223 Tontini GE, Pastorelli L, Ishaq S, Neumann H. Advances in endoscopic imaging in ulcerative colitis. Expert Rev Gastroenterol Hepatol 2015;9:1393-405. [PMID: 26365308 DOI: 10.1586/17474124.2015.1087848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
224 Triantafillidis J, Vagianos C, Agrogiannis G, Gikas A, Douvi G, Syrmos N, Patsouris E, Papalois A. Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron. Journal of Investigative Surgery 2016;30:6-12. [DOI: 10.1080/08941939.2016.1215574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
225 Riddell RH. Mucosal healing in ulcerative colitis: what constitutes remission? Nat Rev Gastroenterol Hepatol 2017;14:5-6. [DOI: 10.1038/nrgastro.2016.194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
226 Pai RK, Hartman DJ, Leighton JA, Pasha SF, Ramos Rivers C, Regueiro M, Binion DG, Pai RK. Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. J Crohns Colitis 2021:jjab042. [PMID: 33687061 DOI: 10.1093/ecco-jcc/jjab042] [Reference Citation Analysis]
227 Crothers JW, Chu ND, Nguyen LTT, Phillips M, Collins C, Fortner K, Del Rio-Guerra R, Lavoie B, Callas P, Velez M, Cohn A, Elliott RJ, Wong WF, Vo E, Wilcox R, Smith M, Kassam Z, Budd R, Alm EJ, Mawe GM, Moses PL. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol 2021;21:281. [PMID: 34238227 DOI: 10.1186/s12876-021-01856-9] [Reference Citation Analysis]
228 Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, Crowley E, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2018;16:1098-1105.e1. [PMID: 29378308 DOI: 10.1016/j.cgh.2018.01.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
229 Xu J, Tam M, Samaei S, Lerouge S, Barralet J, Stevenson MM, Cerruti M. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater 2017;48:247-57. [PMID: 27769943 DOI: 10.1016/j.actbio.2016.10.026] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
230 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
231 El Demellawy D, El Hallani S, de Nanassy J, Lee JY, Chan E, Sullivan K, Bass J, Mack D, Nasr A. Value of histopathology for predicting the post-operative complications of ileo-anal anastomosis (J-pouch) procedure in children with refractory ulcerative colitis. Pathology 2016;48:330-5. [DOI: 10.1016/j.pathol.2016.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
232 Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(20): 723-732 [PMID: 28042386 DOI: 10.4253/wjge.v8.i20.723] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
233 Li B, Li Y, Li L, Yu Y, Gu X, Liu C, Long X, Yu Y, Zuo X. Hsa_circ_0001021 regulates intestinal epithelial barrier function via sponging miR-224-5p in ulcerative colitis. Epigenomics 2021;13:1385-401. [PMID: 34528447 DOI: 10.2217/epi-2021-0230] [Reference Citation Analysis]
234 Suzawa K, Kobayashi M, Sakai Y, Hoshino H, Watanabe M, Harada O, Ohtani H, Fukuda M, Nakayama J. Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. Am J Gastroenterol. 2007;102:1499-1509. [PMID: 17459027 DOI: 10.1111/j.1572-0241.2007.01189.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
235 Soendergaard C, Nielsen OH, Seidelin JB, Kvist PH, Bjerrum JT. Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis. Inflamm Bowel Dis 2015;21:1077-88. [PMID: 25803506 DOI: 10.1097/MIB.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
236 Harpaz N, Ballentine S, Colombel J, E Sands B, Ko HM. Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity. Gut 2020;69:401-2. [DOI: 10.1136/gutjnl-2018-318137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
237 Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016;18:123-30. [PMID: 28458507 DOI: 10.1016/j.tgie.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis: . Inflammatory Bowel Diseases 2012;18:2371-80. [DOI: 10.1002/ibd.22949] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
239 Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2017;7:CD012351. [PMID: 28731502 DOI: 10.1002/14651858.CD012351.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
240 Tan Y, Guan Y, Sun Y, Zheng C. Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients. Am J Med Sci. 2019;357:195-204. [PMID: 30638599 DOI: 10.1016/j.amjms.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
241 Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009;4:e7984. [PMID: 19956723 DOI: 10.1371/journal.pone.0007984] [Cited by in Crossref: 132] [Cited by in F6Publishing: 130] [Article Influence: 10.2] [Reference Citation Analysis]
242 Keita ÅV, Lindqvist CM, Öst Å, Magana CDL, Schoultz I, Halfvarson J. Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn's Disease Predominantly Caused by Genetic Predisposition. J Crohns Colitis 2018;12:1200-9. [PMID: 29659773 DOI: 10.1093/ecco-jcc/jjy045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
243 Fausel RA, Kornbluth A, Dubinsky MC. The First Endoscopy in Suspected Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2016;26:593-610. [PMID: 27633590 DOI: 10.1016/j.giec.2016.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
244 Kucharski M, Karczewski J, Mańkowska-wierzbicka D, Karmelita-katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2016;28:722-30. [DOI: 10.1097/meg.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
245 Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016;111:1692-1701. [PMID: 27725645 DOI: 10.1038/ajg.2016.418] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
246 Mitsuishi T. Correlation between histological findings and endoscopic findings in patients with ulcerative colitis: Basal plasmacytosis is an important finding suggesting active inflammation. JGH Open 2019;3:100-4. [PMID: 31061883 DOI: 10.1002/jgh3.12111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
247 Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
248 van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, Nieuwenhuis EE, van der Woude CJ. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis. 2009;15:193-198. [PMID: 18825773 DOI: 10.1002/ibd.20644] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
249 Guo Q, Tang ZP, Wang LJ. Progress in histopathological diagnosis of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2014; 22(2): 190-196 [DOI: 10.11569/wcjd.v22.i2.190] [Reference Citation Analysis]
250 Tursi A, Elisei W, Picchio M, Zampaletta C, Pelecca G, Faggiani R, Brandimarte G. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. Tech Coloproctol. 2014;18:1041-1046. [PMID: 24915941 DOI: 10.1007/s10151-014-1177-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
251 Ye X, Wang Y, Wang HHX, Feng R, Ye Z, Han J, Li L, Zeng Z, Chen M, Zhang S. Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. Therap Adv Gastroenterol 2021;14:1756284821994741. [PMID: 33717211 DOI: 10.1177/1756284821994741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Hashavia E, Dotan I, Rabau M, Klausner JM, Halpern Z, Tulchinsky H. Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study: Risk factors for chronic pouchitis. Colorectal Disease 2012;14:1365-71. [DOI: 10.1111/j.1463-1318.2012.02993.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
253 Payne SC, Shepherd RK, Sedo A, Fallon JB, Furness JB. An objective in vivo diagnostic method for inflammatory bowel disease. R Soc Open Sci 2018;5:180107. [PMID: 29657828 DOI: 10.1098/rsos.180107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Pai RK, Lauwers GY, Pai RK. Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. Adv Anat Pathol 2022;29:37-47. [PMID: 34879037 DOI: 10.1097/PAP.0000000000000326] [Reference Citation Analysis]
255 Monteleone I, Federici M, Sarra M, Franzè E, Casagrande V, Zorzi F, Cavalera M, Rizzo A, Lauro R, Pallone F, MacDonald TT, Monteleone G. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology 2012;143:1277-1287.e4. [PMID: 22819866 DOI: 10.1053/j.gastro.2012.07.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
256 Wunsch E, Klak M, Wasik U, Milkiewicz M, Blatkiewicz M, Urasinska E, Barbier O, Bielicki D, Bogdanos DP, Elias E, Milkiewicz P. Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR. J Immunol Res 2015;2015:571353. [PMID: 26504856 DOI: 10.1155/2015/571353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
257 Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, Hawkins S, Abbott-Banner K, Tak PP. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680. [PMID: 34389633 DOI: 10.1136/bmjgast-2021-000680] [Reference Citation Analysis]
258 Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr 2018;66:84-9. [PMID: 28604509 DOI: 10.1097/MPG.0000000000001641] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
259 Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020;. [PMID: 33010406 DOI: 10.1016/j.cgh.2020.09.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
260 Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 2020;5:819-28. [PMID: 32553149 DOI: 10.1016/S2468-1253(20)30188-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
261 Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.Am J Gastroenterol. 2020;115:179-189. [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
262 Hao XP, Lucero CM, Turkbey B, Bernardo ML, Morcock DR, Deleage C, Trubey CM, Smedley J, Klatt NR, Giavedoni LD, Kristoff J, Xu A, Del Prete GQ, Keele BF, Rao SS, Alvord WG, Choyke PL, Lifson JD, Brenchley JM, Apetrei C, Pandrea I, Estes JD. Experimental colitis in SIV-uninfected rhesus macaques recapitulates important features of pathogenic SIV infection. Nat Commun 2015;6:8020. [PMID: 26282376 DOI: 10.1038/ncomms9020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
263 Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, Van Lommel L, Quintens R, Van Assche G, Vermeire S. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748-761. [PMID: 21326222 DOI: 10.1038/ajg.2011.27] [Cited by in Crossref: 100] [Cited by in F6Publishing: 102] [Article Influence: 9.1] [Reference Citation Analysis]
264 Kuehbacher T, Rehman A, Lepage P, Hellmig S, Fölsch UR, Schreiber S, Ott SJ. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol. 2008;57:1569-1576. [PMID: 19018031 DOI: 10.1099/jmm.0.47719-0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 8.5] [Reference Citation Analysis]
265 Gui X, Li J, Ueno A, Iacucci M, Qian J, Ghosh S. Histopathological Features of Inflammatory Bowel Disease are Associated With Different CD4+ T Cell Subsets in Colonic Mucosal Lamina Propria. J Crohns Colitis 2018;12:1448-58. [PMID: 30137280 DOI: 10.1093/ecco-jcc/jjy116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
266 Kobayashi K, Tomita H, Shimizu M, Tanaka T, Suzui N, Miyazaki T, Hara A. p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer. Int J Mol Sci 2017;18:E1284. [PMID: 28621756 DOI: 10.3390/ijms18061284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
267 Calafat M, Lobatón T, Hernández-gallego A, Mañosa M, Torres P, Cañete F, Cabré E, Ojanguren I, Domènech E. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. Digestive and Liver Disease 2017;49:1327-31. [DOI: 10.1016/j.dld.2017.08.041] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
268 Geboes K. Pathology of inflammatory bowel diseases (IBD): variability with time and treatment. Colorectal Dis. 2001;3:2-12. [PMID: 12791013 DOI: 10.1111/j.1463-1318.2001.00187.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Zhou Y, Qin D, Wang Y, Yang Q, Zhang C, Dai Q. Amelioration of Tripterygium wilfordii Polycoride on TNBS/Ethanol-induced Ulcerative Colitis via Inhibiting Lipid Peroxidation and Its Downstream Inflammatory Meditors. Chinese Herbal Medicines 2017;9:344-52. [DOI: 10.1016/s1674-6384(17)60114-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
270 Harki J, Sana A, van Noord D, van Diest PJ, van der Groep P, Kuipers EJ, Moons LMG, Biermann K, Tjwa ETTL. Hypoxia-inducible factor 1-α in chronic gastrointestinal ischemia. Virchows Arch 2015;466:125-32. [DOI: 10.1007/s00428-014-1691-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
271 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
272 Abdelrazeq AS, Lund JN, Leveson SH. Implications of pouchitis on the functional results following stapled restorative proctocolectomy. Dis Colon Rectum. 2005;48:1700-1707. [PMID: 15937626 DOI: 10.1007/s10350-005-0058-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
273 Furth EE, Gustafson KS, Dai CY, Gibson SL, Menard-Katcher P, Chen T, Koh J, Enders GH. Induction of the tumor-suppressor p16(INK4a) within regenerative epithelial crypts in ulcerative colitis. Neoplasia 2006;8:429-36. [PMID: 16820088 DOI: 10.1593/neo.06169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
274 Maeda Y, Kudo SE, Mori Y, Misawa M, Ogata N, Sasanuma S, Wakamura K, Oda M, Mori K, Ohtsuka K. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest Endosc. 2019;89:408-415. [PMID: 30268542 DOI: 10.1016/j.gie.2018.09.024] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 18.8] [Reference Citation Analysis]
275 Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016; 22(3): 1017-1033 [PMID: 26811644 DOI: 10.3748/wjg.v22.i3.1017] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
276 Liu L, Liang L, Liang H, Wang M, Lu B, Xue M, Deng J, Chen Y. Fusobacterium nucleatum Aggravates the Progression of Colitis by Regulating M1 Macrophage Polarization via AKT2 Pathway. Front Immunol 2019;10:1324. [PMID: 31249571 DOI: 10.3389/fimmu.2019.01324] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
277 Gore RM, Frank H. M, Yaghmai V, Berlin JW, Newmark G. Inflammatory conditions of the colon. Seminars in Roentgenology 2001;36:126-37. [DOI: 10.1053/sroe.2001.23047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
278 McQueen P, Busman-Sahay K, Rieder F, Noël-Romas L, McCorrister S, Westmacott G, Estes JD, Burgener A. Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction. Mucosal Immunol 2019;12:1327-35. [PMID: 31481749 DOI: 10.1038/s41385-019-0200-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
279 Horváth G, Farkas K, Hollósi R, Nagy F, Szepes Z, Papp M, Palatka K, Miheller P, Lakatos L, Szamosi T, Nyári T, Wittmann T, Molnár T. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol 2012;47:1298-303. [PMID: 22935014 DOI: 10.3109/00365521.2012.703233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
280 Petrolis R, Ramonaitė R, Jančiauskas D, Kupčinskas J, Pečiulis R, Kupčinskas L, Kriščiukaitis A. Digital imaging of colon tissue: method for evaluation of inflammation severity by spatial frequency features of the histological images. Diagn Pathol 2015;10:159. [PMID: 26370784 DOI: 10.1186/s13000-015-0389-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
281 Uchida K, Araki T, Hashimoto K, Inoue M, Otake K, Koike Y, Okita Y, Fujikawa H, Tanaka K, Mohri Y, Kusunoki M. Segmental distribution in refractory ulcerative colitis: a histological evaluation in pediatric and adult patients who underwent proctocolectomy. Inflamm Bowel Dis 2014;20:1227-35. [PMID: 24865779 DOI: 10.1097/MIB.0000000000000082] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
282 Roosenboom B, Horjus Talabur Horje CS, Smids C, Leeuwis JW, van Koolwijk E, Groenen MJM, Wahab PJ, van Lochem EG. Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies. Scand J Gastroenterol 2021;56:671-9. [PMID: 33779456 DOI: 10.1080/00365521.2021.1906316] [Reference Citation Analysis]
283 Berry N, Sinha SK, Bhattacharya A, Prasad KK, Vaishnavi C, Vaiphei K, Samanta J, Prasada R, Dhaka N, Kochhar R. Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers. Dig Dis Sci 2018;63:1541-50. [DOI: 10.1007/s10620-018-5026-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
284 Block M, Mölne J, Leffler H, Börjesson L, Breimer ME. Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. Biomed Res Int 2016;2016:5989128. [PMID: 26885508 DOI: 10.1155/2016/5989128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
285 Pai RK, Geboes K. Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? Virchows Arch. 2018;472:99-110. [PMID: 28555281 DOI: 10.1007/s00428-017-2156-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
286 Smith PJ, Levine AP, Dunne J, Guilhamon P, Turmaine M, Sewell GW, OʼShea NR, Vega R, Paterson JC, Oukrif D. Mucosal Transcriptomics Implicates Under Expression of BRINP3 in the Pathogenesis of Ulcerative Colitis. Inflamm Bowel Dis. 2014;20:1802-1812. [PMID: 25171508 DOI: 10.1097/MIB.0000000000000169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
287 Magro F, Lopes S, Coelho R, Cotter J, de Castro FD, de Sousa HT, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Chagas C, Torres J, Dias CC, Lopes J, Borralho P, Afonso J, Geboes K, Carneiro F; on behalf of the Portuguese IBD Study Group [GEDII]. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis—the ACERTIVE study. ECCOJC. [DOI: 10.1093/ecco-jcc/jjw170] [Reference Citation Analysis]
288 Mcgowan I, Cranston RD, Duffill K, Siegel A, Engstrom JC, Nikiforov A, Jacobson C, Rehman KK, Elliott J, Khanukhova E, Abebe K, Mauck C, Spiegel HM, Dezzutti CS, Rohan LC, Marzinke MA, Hiruy H, Hendrix CW, Richardson-Harman N, Anton PA. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). PLoS One 2015;10:e0125363. [PMID: 25942472 DOI: 10.1371/journal.pone.0125363] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
289 Pearl DS, Shah K, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK, Trebble TM. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohns Colitis. 2013;7:481-489. [PMID: 22974822 DOI: 10.1016/j.crohns.2012.07.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
290 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
291 Bekheit M, Baddour N, Katri K, Taher Y, El Tobgy K, Mousa E. Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. BMJ Open Gastroenterol. 2016;3:e000082. [PMID: 27195128 DOI: 10.1136/bmjgast-2016-000082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
292 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
293 Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, Watschinger C, Koch R, Effenberger M, Raine T, Tilg H, Moschen AR. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2—a Comparative Study. Journal of Crohn's and Colitis 2021;15:43-54. [DOI: 10.1093/ecco-jcc/jjaa124] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
294 Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, Trebble TM. Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology. PLoS One 2013;8:e76532. [PMID: 24204637 DOI: 10.1371/journal.pone.0076532] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
295 Kanmura S, Hamamoto H, Tanaka A, Arima S, Sasaki F, Tanoue S, Nasu Y, Hashimoto S, Higashi M, Ido A. Diagnostic utility of linked color imaging in the evaluation of colonic mucosal inflammation in ulcerative colitis: a pilot study. Endosc Int Open 2019;7:E937-43. [PMID: 31367672 DOI: 10.1055/a-0810-0398] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
296 Gubatan J, Mitsuhashi S, Zenlea T, Rosenberg L, Robson S, Moss AC. Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2017; 15: 240-246. e1. [PMID: 27266980 DOI: 10.1016/j.cgh.2016.05.035] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
297 Gundersen MD, Goll R, Fenton CG, Anderssen E, Sørbye SW, Florholmen JR, Paulssen RH. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin Transl Gastroenterol 2019;10:e00082. [PMID: 31584460 DOI: 10.14309/ctg.0000000000000082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
298 Wasmann KA, van der Does de Willebois EM, Koens L, Duijvestein M, Bemelman WA, Buskens CJ. The Impact of Rectal Stump Inflammation After Subtotal Colectomy on Pouch Outcomes in Ulcerative Colitis Patients. J Crohns Colitis 2020:jjaa157. [PMID: 32901798 DOI: 10.1093/ecco-jcc/jjaa157] [Reference Citation Analysis]
299 Soga K, Itani K. Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance. Clin J Gastroenterol 2019;12:578-82. [DOI: 10.1007/s12328-019-00985-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
300 Li Y, Nuij VJ, Baars JE, Biermann K, Kuipers EJ, Peppelenbosch MP, de Haar C, Janneke van der Woude C. Increased Suppressor of Cytokine Signaling-3 Expression Predicts Mucosal Relapse in Ulcerative Colitis: . Inflammatory Bowel Diseases 2013;19:132-40. [DOI: 10.1002/ibd.22992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
301 Maione F, Giglio MC, Luglio G, Rispo A, D'Armiento M, Manzo B, Cassese G, Schettino P, Gennarelli N, Siciliano S, D'Armiento FP, De Palma GD. Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol 2017;21:531-40. [PMID: 28674950 DOI: 10.1007/s10151-017-1654-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
302 Narang V, Kaur R, Garg B, Mahajan R, Midha V, Sood N, Sood A. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;16:55-61. [PMID: 29422798 DOI: 10.5217/ir.2018.16.1.55] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
303 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513-22. [PMID: 20676771 DOI: 10.1007/s10620-010-1334-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
304 Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol. 2006;126:365-376. [PMID: 16880149 DOI: 10.1309/uaxmw3428pgn9hj3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
305 Millecam J, van Bergen T, Schauvliege S, Antonissen G, Martens A, Chiers K, Gehring R, Gasthuys E, Vande Walle J, Croubels S, Devreese M. Developmental Pharmacokinetics and Safety of Ibuprofen and Its Enantiomers in the Conventional Pig as Potential Pediatric Animal Model. Front Pharmacol 2019;10:505. [PMID: 31143123 DOI: 10.3389/fphar.2019.00505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
306 Ekanayaka A, Anderson JT, Lucarotti ME, Valori RM, Shepherd NA. The isolated caecal patch lesion: a clinical, endoscopic and histopathological study. J Clin Pathol 2020;73:121-5. [DOI: 10.1136/jclinpath-2019-206146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
307 Yan B, Feagan B, Teriaky A, Mosli M, Mohamed R, Williams G, Yeung E, Yong E, Haig A, Sey M, Stitt L, Zou GY, Jairath V. Reliability of EUS indices to detect inflammation in ulcerative colitis. Gastrointest Endosc 2017;86:1079-87. [PMID: 28760533 DOI: 10.1016/j.gie.2017.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
308 Magro F, Lopes S, Coelho R, Cotter J, Dias de Castro F, Tavares de Sousa H, Salgado M, Andrade P, Vieira AI, Figueiredo P. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. J Crohns Colitis. 2017;11:435-444. [PMID: 27664275 DOI: 10.1093/ecco-jcc/jjw170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
309 Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, de Hertogh G, Robert ME, Valasek MA, Mao R, Li J, Harpaz N, Borralho P, Pai RK, Odze R, Feakins R, Parker CE, Guizzetti L, Nguyen T, Shackelton LM, Sandborn WJ, Jairath V, Baker M, Bruining D, Fletcher JG, Feagan BG, Pai RK, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. Gut 2021:gutjnl-2021-324374. [PMID: 33952604 DOI: 10.1136/gutjnl-2021-324374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Bhattacharya N, Yuan R, Prestwood TR, Penny HL, DiMaio MA, Reticker-Flynn NE, Krois CR, Kenkel JA, Pham TD, Carmi Y, Tolentino L, Choi O, Hulett R, Wang J, Winer DA, Napoli JL, Engleman EG. Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer. Immunity. 2016;45:641-655. [PMID: 27590114 DOI: 10.1016/j.immuni.2016.08.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
311 Melson JE, Giusto D, Kwasny M, Eichenseer P, Jakate S, Keshavarzian A. Histopathology Predictors of Medically Refractory Ulcerative Colitis. Diseases of the Colon & Rectum 2010;53:1280-6. [DOI: 10.1007/dcr.0b013e3181e751df] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
312 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
313 Baars JE, Vogelaar L, Wolfhagen FH, Biermann K, Kuipers EJ, van der Woude CJ. A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial. J Crohns Colitis. 2010;4:661-668. [PMID: 21122577 DOI: 10.1016/j.crohns.2010.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
314 Lee SH, Kwon JY, Moon J, Choi J, Jhun J, Jung K, Cho KH, Darlami O, Lee HH, Jung ES, Shin DY, Lee BI, Cho ML. Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients. Immune Netw 2020;20:e16. [PMID: 32395368 DOI: 10.4110/in.2020.20.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Finkel Y, Eberhardson M. Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease. Nutrients 2019;11:E414. [PMID: 30781421 DOI: 10.3390/nu11020414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
316 Uchiyama K, Takagi T, Mizushima K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Tanaka M, Hotta Y, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Naito Y, Itoh Y. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterol 2021;21:122. [PMID: 33730998 DOI: 10.1186/s12876-021-01709-5] [Reference Citation Analysis]
317 Rodríguez-Perálvarez ML, García-Sánchez V, Villar-Pastor CM, González R, Iglesias-Flores E, Muntane J, Gómez-Camacho F. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis. 2012;18:1864-1871. [PMID: 22238172 DOI: 10.1002/ibd.22865] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
318 Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012;143:62-69.e4. [PMID: 22504093 DOI: 10.1053/j.gastro.2012.04.010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
319 Dragasevic S, Sokic-Milutinovic A, Stojkovic Lalosevic M, Milovanovic T, Djuranovic S, Jovanovic I, Rajic S, Stojkovic M, Milicic B, Kmezic S, Oluic B, Aleksic M, Pavlovic Markovic A, Popovic D. Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients. Gastroenterol Res Pract 2020;2020:2065383. [PMID: 32328091 DOI: 10.1155/2020/2065383] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 27.1] [Reference Citation Analysis]
321 Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-biroulet L, Brodmerkel C, De Hertogh G. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. Journal of Crohn's and Colitis 2019;13:1025-35. [DOI: 10.1093/ecco-jcc/jjz022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
322 Lie MRKL, Kreijne JE, Dijkstra G, Löwenberg M, van Assche G, West RL, van Noord D, van der Meulen-de Jong AE, Oldenburg B, Zaal RJ, Hansen BE, de Vries AC, Janneke van der Woude C; Dutch Initiative on Crohn and Colitis. No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol 2020;18:1777-1784.e2. [PMID: 31610337 DOI: 10.1016/j.cgh.2019.09.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
323 McGowan IM, Tzakis N, Kosak B, Korczak B, Engstrom J, Tomaszewska-Kiecana M, Hartley O. Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers. AIDS Res Hum Retroviruses 2021;37:453-60. [PMID: 33749321 DOI: 10.1089/AID.2021.0010] [Reference Citation Analysis]
324 Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Castro FDD, Sousa HTD, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Rosa I, Rodrigues M, Chagas C, Dias CC, Afonso J, Geboes K, Carneiro F. Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2019;68:594-603. [DOI: 10.1136/gutjnl-2017-315545] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
325 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. European Journal of Internal Medicine 2014;25:485-90. [DOI: 10.1016/j.ejim.2014.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
326 Tulchinsky H, Dotan I, Alper A, Brazowski E, Klausner JM, Halpern Z, Rabau M. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: report of 3 years’ experience in a tertiary referral center. Inflamm Bowel Dis. 2008;14:1125-1132. [PMID: 18338779 DOI: 10.1002/ibd.20430] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
327 Hasdemir B, Mhaske P, Paruthiyil S, Garnett EA, Heyman MB, Matloubian M, Bhargava A. Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation. Am J Physiol Regul Integr Comp Physiol 2016;310:R1244-57. [PMID: 27053649 DOI: 10.1152/ajpregu.00445.2015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
328 Ahn HJ, Kang SB. Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis? Intest Res 2018;16:1-3. [PMID: 29422792 DOI: 10.5217/ir.2018.16.1.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis W. Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?: . Inflammatory Bowel Diseases 2013;19:2611-5. [DOI: 10.1097/01.mib.0000437044.43961.00] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
330 Wang X, Shen B. Management of Crohn’s Disease and Complications in Patients With Ostomies. Inflammatory Bowel Diseases 2018;24:1167-84. [DOI: 10.1093/ibd/izy025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
331 Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634-646. [PMID: 23680148 DOI: 10.1016/j.ccr.2013.03.022] [Cited by in Crossref: 257] [Cited by in F6Publishing: 253] [Article Influence: 28.6] [Reference Citation Analysis]
332 Iqbal H, Kim SK, Cha KM, Jeong MS, Ghosh P, Rhee DK. Korean Red Ginseng alleviates neuroinflammation and promotes cell survival in the intermittent heat stress-induced rat brain by suppressing oxidative stress via estrogen receptor beta and brain-derived neurotrophic factor upregulation. J Ginseng Res 2020;44:593-602. [PMID: 32617039 DOI: 10.1016/j.jgr.2019.05.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
333 de Bruyn M, Machiels K, Vandooren J, Lemmens B, Van Lommel L, Breynaert C, Van der Goten J, Staelens D, Billiet T, De Hertogh G, Ferrante M, Van Assche G, Vermeire S, Opdenakker G, Schuit F, Rutgeerts P, Arijs I. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:339-52. [PMID: 24378596 DOI: 10.1097/01.MIB.0000438430.15553.90] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
334 Münch A, Söderholm JD, Wallon C, Ost A, Olaison G, Ström M. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut. 2005;54:1126-1128. [PMID: 16009686 DOI: 10.1136/gut.2004.058750] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
335 Kalra J, Lingaraju MC, Mathesh K, Kumar D, Parida S, Singh TU, Sharma AK, Kumar D, Tandan SK. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn-Schmiedeberg's Arch Pharmacol 2018;391:285-97. [DOI: 10.1007/s00210-017-1455-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
336 Ciccocioppo R, Imbesi V, Betti E, Boccaccio V, Kruzliak P, Gallia A, Cangemi GC, Maffe GC, Vanoli A, Merante S, De Amici M, Falcone C, Klersy C, Corazza GR. The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study. Dig Dis Sci 2015;60:2327-37. [PMID: 25757448 DOI: 10.1007/s10620-015-3619-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
337 Tursi A, Elisei W, Picchio M, Forti G, Penna A, Inchingolo CD, Nenna R, Brandimarte G. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. Clin Res Hepatol Gastroenterol. 2015;39:107-113. [PMID: 25176588 DOI: 10.1016/j.clinre.2014.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
338 Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther 2020;52:1574-82. [PMID: 32981088 DOI: 10.1111/apt.16083] [Reference Citation Analysis]
339 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
340 Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27:1418-1424. [PMID: 26308711 DOI: 10.1097/meg.0000000000000461] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
341 Mitomi H, Ohkura Y, Yokoyama K, Sada M, Kobayashi K, Tanabe S, Fukui N, Kanazawa H, Kishimoto I, Saigenji K. Contribution of TIA-1+ and granzyme B+ cytotoxic T lymphocytes to cryptal apoptosis and ulceration in active inflammatory bowel disease. Pathology - Research and Practice 2007;203:717-23. [DOI: 10.1016/j.prp.2007.06.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
342 McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, Carballo-Dieguez A, Ayudhya RK, Piper J, Hladik F, Mayer K. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 2013;8:e60147. [PMID: 23573238 DOI: 10.1371/journal.pone.0060147] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
343 Römkens TEH, Kranenburg P, Tilburg AV, Bronkhorst C, Nagtegaal ID, Drenth JPH, Hoentjen F. Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. J Crohns Colitis 2018;12:425-31. [PMID: 29240880 DOI: 10.1093/ecco-jcc/jjx165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
344 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology 2021:S0016-5085(21)03126-7. [PMID: 34144047 DOI: 10.1053/j.gastro.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Lopetuso LR, Corbi M, Scaldaferri F, Petito V, Graziani C, Castri F, Neri M, Gasbarrini A, Sgambato A, Papa A. Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment. Eur J Gastroenterol Hepatol 2020;32:1527-32. [PMID: 32976192 DOI: 10.1097/MEG.0000000000001933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Martini M, Ferrara AM, Giachelia M, Panieri E, Siminovitch K, Galeotti T, Larocca LM, Pani G. Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. Inflamm Bowel Dis. 2012;18:439-448. [PMID: 21793125 DOI: 10.1002/ibd.21814] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
347 Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827-851. [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001] [Cited by in Crossref: 336] [Cited by in F6Publishing: 273] [Article Influence: 37.3] [Reference Citation Analysis]
348 Gordon IO, Agrawal N, Goldblum JR, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis. 2014;20:2198-2206. [PMID: 24892966 DOI: 10.1097/mib.0000000000000080] [Cited by in Crossref: 59] [Cited by in F6Publishing: 27] [Article Influence: 8.4] [Reference Citation Analysis]
349 Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384:309-318. [PMID: 24814090 DOI: 10.1016/s0140-6736(14)60661-9] [Cited by in Crossref: 295] [Cited by in F6Publishing: 117] [Article Influence: 36.9] [Reference Citation Analysis]
350 Conrad MA, Carreon CK, Dawany N, Russo P, Kelsen JR. Distinct Histopathological Features at Diagnosis of Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis 2019;13:615-25. [PMID: 30551128 DOI: 10.1093/ecco-jcc/jjy212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
351 Takagi T, Uchiyama K, Kajiwara-Kubota M, Kashiwagi S, Toyokawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Yoshida N, Kamada K, Ishikawa T, Konishi H, Kishimoto M, Yagi N, Naito Y, Itoh Y. The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 33710655 DOI: 10.1111/jgh.15489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology 2016;150:1056-60. [PMID: 27018491 DOI: 10.1053/j.gastro.2016.03.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
353 Yasutomi E, Inokuchi T, Hiraoka S, Takei K, Igawa S, Yamamoto S, Ohmori M, Oka S, Yamasaki Y, Kinugasa H, Takahara M, Harada K, Furukawa M, Itoshima K, Okada K, Otsuka F, Tanaka T, Mitsuhashi T, Kato J, Okada H. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci Rep 2021;11:11086. [PMID: 34045529 DOI: 10.1038/s41598-021-90441-x] [Reference Citation Analysis]
354 Gonzalez-pujana A, Beloqui A, Javier Aguirre J, Igartua M, Santos-vizcaino E, Maria Hernandez R. Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation. European Journal of Pharmaceutics and Biopharmaceutics 2022. [DOI: 10.1016/j.ejpb.2022.01.007] [Reference Citation Analysis]
355 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
356 Mounzer R, Yen R, Marshall C, Sams S, Mehrotra S, Said MS, Obuch JC, Brauer B, Attwell A, Fukami N, Shah R, Amateau S, Hall M, Hosford L, Wilson R, Rastogi A, Wani S. Interobserver agreement among cytopathologists in the evaluation of pancreatic endoscopic ultrasound-guided fine needle aspiration cytology specimens. Endosc Int Open. 2016;4:E812-E819. [PMID: 27556103 DOI: 10.1055/s-0042-108188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
357 Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, Ferrante M, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut. 2020;69:1778-1786. [PMID: 31915237 DOI: 10.1136/gutjnl-2019-320056] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
358 Gamo K, Okuzono Y, Yabuki M, Ochi T, Sugimura K, Sato Y, Sagara M, Hayashi H, Ishimura Y, Nishimoto Y, Murakawa Y, Shiokawa Z, Gotoh M, Miyazaki T, Ebisuno Y. Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease. Inflamm Bowel Dis 2018;24:1251-65. [PMID: 29669006 DOI: 10.1093/ibd/izy079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
359 Löwenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. Gastroenterology 2019;157:997-1006.e6. [PMID: 31175865 DOI: 10.1053/j.gastro.2019.05.067] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
360 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
361 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
362 Patil DT, Moss AC, Odze RD. Role of Histologic Inflammation in the Natural History of Ulcerative Colitis. Gastrointest Endosc Clin N Am 2016;26:629-40. [PMID: 27633592 DOI: 10.1016/j.giec.2016.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
363 Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh SM, Neishaboori H. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321-8. [DOI: 10.1007/s11739-014-1144-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
364 Khairy H, Saleh H, Badr AM, Marie MS. Therapeutic efficacy of osthole against dinitrobenzene sulphonic acid induced-colitis in rats. Biomedicine & Pharmacotherapy 2018;100:42-51. [DOI: 10.1016/j.biopha.2018.01.104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
365 Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Dias de Castro F, Tavares de Sousa H, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Chagas C, Cravo M, Dias CC, Afonso J, Portela F, Santiago M, Geboes K, Carneiro F. Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. Journal of Crohn's and Colitis 2020;14:169-75. [DOI: 10.1093/ecco-jcc/jjz123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
366 Nardone OM, Cannatelli R, Zardo D, Ghosh S, Iacucci M. Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? Therap Adv Gastroenterol 2019;12:1756284819863015. [PMID: 31360224 DOI: 10.1177/1756284819863015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
367 De Preter V, Bulteel V, Suenaert P, Geboes KP, De Hertogh G, Luypaerts A, Geboes K, Verbeke K, Rutgeerts P. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm Bowel Dis. 2009;15:335-340. [PMID: 18942762 DOI: 10.1002/ibd.20768] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
368 Ren T, Tian T, Feng X, Ye S, Wang H, Wu W, Qiu Y, Yu C, He Y, Zeng J, Cen J, Zhou Y. An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway. Sci Rep 2015;5:9047. [PMID: 25762375 DOI: 10.1038/srep09047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
369 Liñán-Rico A, Wunderlich JE, Grants IS, Frankel WL, Xue J, Williams KC, Harzman AE, Enneking JT, Cooke HJ, Christofi FL. Purinergic autocrine regulation of mechanosensitivity and serotonin release in a human EC model: ATP-gated P2X3 channels in EC are downregulated in ulcerative colitis. Inflamm Bowel Dis 2013;19:2366-79. [PMID: 23917247 DOI: 10.1097/MIB.0b013e31829ecf4d] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
370 Xu AT, Li Y, Zhao D, Shen J, Xu XT, Qiao YQ, Zhu MM, Wang TR, Cui Y, Ai LY, Ran ZH. High Suppressor of Cytokine Signaling-3 Expression Impairs STAT3-dependent Protective Effects of Interleukin-22 in Ulcerative Colitis in Remission: . Inflammatory Bowel Diseases 2015;21:241-50. [DOI: 10.1097/mib.0000000000000267] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
371 de Paula-Silva M, Barrios BE, Macció-Maretto L, Sena AA, Farsky SH, Correa SG, Oliani SM. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis. Biochem Pharmacol 2016;115:104-13. [PMID: 27343762 DOI: 10.1016/j.bcp.2016.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
372 Zagórowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mróz A. Cytomegalovirus Infection in Ulcerative Colitis is Related to Severe Inflammation and a High Count of Cytomegalovirus-positive Cells in Biopsy Is a Risk Factor for Colectomy. ECCOJC 2016;10:1205-11. [DOI: 10.1093/ecco-jcc/jjw071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
373 Mahajan S, Liao M, Barkan P, Takahashi K, Bhargava A. Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk. Peptides 2014;54:58-66. [PMID: 24462512 DOI: 10.1016/j.peptides.2014.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
374 Green N, Lee D, Wahbeh G, Pacheco MC. Do Histologic Features Help Predict Colectomy in Pediatric Patients Presenting With Acute Severe Colitis? Pediatr Dev Pathol 2020;23:380-6. [PMID: 32511053 DOI: 10.1177/1093526620929477] [Reference Citation Analysis]
375 Stepankova R, Powrie F, Kofronova O, Kozakova H, Hudcovic T, Hrncir T, Uhlig H, Read S, Rehakova Z, Benada O. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis. 2007;13:1202-1211. [PMID: 17607724 DOI: 10.1002/ibd.20221] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 10.4] [Reference Citation Analysis]
376 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Malham M, James JP, Jakobsen C, Hoegdall E, Holmstroem K, Wewer V, Nielsen BS, Riis LB. Mucosal microRNAs relate to age and severity of disease in ulcerative colitis. Aging (Albany NY) 2021;13:6359-74. [PMID: 33647883 DOI: 10.18632/aging.202715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
378 Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, Devenport M, Zheng P, Zhang XL, Lian XD, Ye M, Zheng HY, Pang W, Zhang GH, Zhang LG, Liu Y, Zheng YT. CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS. Antiviral Res 2018;157:9-17. [PMID: 29983395 DOI: 10.1016/j.antiviral.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
379 Devisscher L, Hindryckx P, Lynes MA, Waeytens A, Cuvelier C, De Vos F, Vanhove C, Vos MD, Laukens D. Role of metallothioneins as danger signals in the pathogenesis of colitis. J Pathol 2014;233:89-100. [PMID: 24452846 DOI: 10.1002/path.4330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
380 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
381 Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H, Oshima S, Akiyama S, Motobayashi M, Nagahori M, Saito E, Matsuoka K, Watanabe M. Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. Gastroenterology. 2020;158:2150-2157. [PMID: 32060000 DOI: 10.1053/j.gastro.2020.02.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 25.0] [Reference Citation Analysis]
382 Stakenborg M, Verstockt B, Meroni E, Goverse G, De Simone V, Verstockt S, Di Matteo M, Czarnewski P, Villablanca EJ, Ferrante M, Boeckxstaens GE, Mazzone M, Vermeire S, Matteoli G. Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. J Crohns Colitis 2020:jjaa121. [PMID: 32556102 DOI: 10.1093/ecco-jcc/jjaa121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
383 Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis 2016;22:607-14. [PMID: 26595549 DOI: 10.1097/MIB.0000000000000597] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
384 Vande Casteele N, Leighton JA, Pasha SF, Cusimano F, Mookhoek A, Hagen CE, Rosty C, Pai RK, Pai RK. Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. Inflamm Bowel Dis 2021:izab122. [PMID: 34106256 DOI: 10.1093/ibd/izab122] [Reference Citation Analysis]
385 Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, Burrell LM, Patel SK, Beswick L, Jackson A, Britto K, Lukies M, Sluka P, Wardan H, Hirokawa Y, Tan CW, Faux M, Burgess AW, Hosking P, Monagle S, Thomas M, Gibson PR, Lubel J. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut 2020;69:841-51. [PMID: 31409604 DOI: 10.1136/gutjnl-2019-318512] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 24.7] [Reference Citation Analysis]
386 Fluxá D, Simian D, Flores L, Ibáñez P, Lubascher J, Figueroa C, Kronberg U, Pizarro G, Castro M, Piottante A, Vial MT, Quera R. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis: Correlation in ulcerative colitis. Journal of Digestive Diseases 2017;18:634-41. [DOI: 10.1111/1751-2980.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
387 Li Y, Pan H, Liu J, Li T, Liu S, Shi W, Sun C, Fan M, Xue L, Wang Y, Nie C, Zhang H, Qian H, Ying H, Wang L. l -Arabinose Inhibits Colitis by Modulating Gut Microbiota in Mice. J Agric Food Chem 2019;67:13299-306. [DOI: 10.1021/acs.jafc.9b05829] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
388 Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:129-143. [PMID: 21694814 DOI: 10.1177/1756283x11398930] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
389 Tertychnyi AS, Akhrieva KM, Maev IV, Zayratyants OV, Selivanova LS. [Diagnostic problems of histological remission in patients with inflammatory bowel disease]. Arkh Patol 2017;79:3-9. [PMID: 28631710 DOI: 10.17116/patol20177933-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018;155:1008-1011.e8. [PMID: 29981298 DOI: 10.1053/j.gastro.2018.06.077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
391 Ma Y, Yue J, Zhang Y, Shi C, Odenwald M, Liang WG, Wei Q, Goel A, Gou X, Zhang J, Chen SY, Tang WJ, Turner JR, Yang F, Liang H, Qin H, Wu X. ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nat Commun 2017;8:15375. [PMID: 28541346 DOI: 10.1038/ncomms15375] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
392 de Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. J Crohns Colitis 2015;9:966-72. [PMID: 26245217 DOI: 10.1093/ecco-jcc/jjv133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
393 Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. American Journal of Gastroenterology 2016;111:685-90. [DOI: 10.1038/ajg.2016.50] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 16.2] [Reference Citation Analysis]
394 Qin Q, Zhu Y, Wu P, Fan X, Huang Y, Huang B, Wang J, Wang L. Radiation-induced injury on surgical margins: a clue to anastomotic leakage after rectal-cancer resection with neoadjuvant chemoradiotherapy? Gastroenterol Rep (Oxf) 2019;7:98-106. [PMID: 30976422 DOI: 10.1093/gastro/goy042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
395 Vargas G, Vincent KL, Zhu Y, Szafron D, Brown TC, Villarreal PP, Bourne N, Milligan GN, Motamedi M. In Vivo Rectal Mucosal Barrier Function Imaging in a Large-Animal Model by Using Confocal Endomicroscopy: Implications for Injury Assessment and Use in HIV Prevention Studies. Antimicrob Agents Chemother 2016;60:4600-9. [PMID: 27185807 DOI: 10.1128/AAC.00134-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
396 Osterman MT, Scott FI, Fogt FF, Gilroy ED, Parrott S, Galanko J, Cross R, Moss A, Herfarth HH, Higgins PDR. Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE). Inflamm Bowel Dis 2021;27:207-14. [PMID: 32170946 DOI: 10.1093/ibd/izaa048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
397 Narula N, Wong ECL, Colombel JF, Riddell R, Marshall JK, Reinisch W, Dulai PS. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00716-3. [PMID: 34229037 DOI: 10.1016/j.cgh.2021.07.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
398 Arkteg CB, Wergeland Sørbye S, Buhl Riis L, Dalen SM, Florholmen J, Goll R. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One 2021;16:e0248224. [PMID: 33684168 DOI: 10.1371/journal.pone.0248224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol. 2010;59:1114-1122. [PMID: 20522625 DOI: 10.1099/jmm.0.021170-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
400 Tursi A. Histologic healing in inflammatory bowel disease clinical practice: a reliable target? Clin Gastroenterol Hepatol 2015;13:1211-2. [PMID: 25066839 DOI: 10.1016/j.cgh.2014.07.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
401 Earley H, Lennon G, Balfe Á, Coffey JC, Winter DC, O'Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep 2019;9:15683. [PMID: 31666581 DOI: 10.1038/s41598-019-51878-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
402 Maeda Y, Kudo SE, Ogata N, Mori Y, Misawa M, Homma M, Nemoto T, Ogawa M, Sasanuma S, Sato Y, Kataoka S, Kouyama Y, Sakurai T, Igarashi K, Ogawa Y, Kato K, Ichimasa K, Nakamura H, Kudo T, Hayashi T, Wakamura K, Baba T, Inoue H, Ohtsuka K. Endocytoscopic intramucosal capillary network changes and crypt architecture abnormalities can predict relapse in patients with an ulcerative colitis Mayo endoscopic score of 1. Dig Endosc 2020;32:1082-91. [PMID: 32073691 DOI: 10.1111/den.13655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
403 Yancu D, Blouin MJ, Birman E, Florianova L, Aleynikova O, Zakikhani M, VanderMeulen H, Seidman E, Pollak M. A phenotype of IGFBP-3 knockout mice revealed by dextran sulfate-induced colitis. J Gastroenterol Hepatol 2017;32:146-53. [PMID: 27253188 DOI: 10.1111/jgh.13461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
404 Liu CY, Cham CM, Chang EB. Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier. Transl Res 2021;236:35-51. [PMID: 34126257 DOI: 10.1016/j.trsl.2021.06.001] [Reference Citation Analysis]
405 Wasmann KATGM, van Amesfoort J, van Montfoort ML, Koens L, Bemelman WA, Buskens CJ. The Predictive Value of Inflammation at Ileocecal Resection Margins for Postoperative Crohn's Recurrence: A Cohort Study. Inflamm Bowel Dis 2020;26:1691-9. [PMID: 31879766 DOI: 10.1093/ibd/izz290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
406 Lee JJ, Rothenberg ME, Seeley ES, Zimdahl B, Kawano S, Lu WJ, Shin K, Sakata-Kato T, Chen JK, Diehn M, Clarke MF, Beachy PA. Control of inflammation by stromal Hedgehog pathway activation restrains colitis. Proc Natl Acad Sci U S A 2016;113:E7545-53. [PMID: 27815529 DOI: 10.1073/pnas.1616447113] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
407 Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15:760-768. [PMID: 19067432 DOI: 10.1002/ibd.20816] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 6.4] [Reference Citation Analysis]
408 Neunlist M, Aubert P, Toquet C, Oreshkova T, Barouk J, Lehur PA, Schemann M, Galmiche JP. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut. 2003;52:84-90. [PMID: 12477766 DOI: 10.1136/gut.52.1.84] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 6.4] [Reference Citation Analysis]
409 Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis: . Inflammatory Bowel Diseases 2006;12:537-42. [DOI: 10.1097/01.ibd.0000225345.29603.7d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
410 Papada E, Kaliora AC, Gioxari A, Papalois A, Forbes A. Anti-inflammatory effect of elemental diets with different fat composition in experimental colitis. Br J Nutr 2014;111:1213-20. [DOI: 10.1017/s0007114513003632] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
411 Van der Goten J, Vanhove W, Lemaire K, Van Lommel L, Machiels K, Wollants WJ, De Preter V, De Hertogh G, Ferrante M, Van Assche G. Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. PLoS One. 2014;9:e116117. [PMID: 25546151 DOI: 10.1371/journal.pone.0116117] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
412 Li Q, Cui Y, Xu B, Wang Y, Lv F, Li Z, Li H, Chen X, Peng X, Chen Y, Wu E, Qu D, Jian Y, Si H. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner. Pharmacol Res 2021;170:105694. [PMID: 34087350 DOI: 10.1016/j.phrs.2021.105694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
413 Xue X, Falcon DM. The Role of Immune Cells and Cytokines in Intestinal Wound Healing. Int J Mol Sci 2019;20:E6097. [PMID: 31816903 DOI: 10.3390/ijms20236097] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
414 Carlsen K, Riis LB, Elsberg H, Maagaard L, Thorkilgaard T, Sørbye SW, Jakobsen C, Wewer V, Florholmen J, Goll R, Munkholm P. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol 2018;53:825-30. [PMID: 29968483 DOI: 10.1080/00365521.2018.1482956] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
415 Bhatnagar G, Rodriguez-Justo M, Higginson A, Bassett P, Windsor A, Cohen R, Halligan S, Taylor SA. Inflammation and fibrosis in Crohn's disease: location-matched histological correlation of small bowel ultrasound features. Abdom Radiol (NY) 2021;46:144-55. [PMID: 32564208 DOI: 10.1007/s00261-020-02603-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohns Colitis 2019;13:424-30. [PMID: 30445625 DOI: 10.1093/ecco-jcc/jjy184] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
417 Magro F, Afonso J, Lopes S, Coelho R, Gonçalves R, Caldeira P, Lago P, de Sousa HT, Ramos J, Gonçalves AR, Ministro P, Rosa I, Meira T, Andrade P, Soares JB, Carvalho D, Sousa P, Vieira AI, Lopes J, Dias CC, Geboes K, Carneiro F. Clinical performance of an infliximab rapid quantification assay. Therap Adv Gastroenterol 2017;10:651-60. [PMID: 28932267 DOI: 10.1177/1756283X17722916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
418 El-bassat H, Aboali L, El Yamany S, Al Shenawy H, Al Din RA, Taha A. Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. Advances in Digestive Medicine 2016;3:88-94. [DOI: 10.1016/j.aidm.2015.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
419 Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 2019;49:1301-13. [PMID: 30895635 DOI: 10.1111/apt.15227] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
420 Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107:1684-1692. [PMID: 23147523 DOI: 10.1038/ajg.2012.301] [Cited by in Crossref: 171] [Cited by in F6Publishing: 152] [Article Influence: 17.1] [Reference Citation Analysis]
421 Tsuda S, Carreras J, Kikuti YY, Nakae H, Dekiden-Monma M, Imai J, Tsuruya K, Nakamura J, Tsukune Y, Uchida T, Matsushima M, Roncador G, Suzuki T, Nakamura N, Mine T. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Pathol Int 2019;69:260-71. [PMID: 30990953 DOI: 10.1111/pin.12794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
422 Poulsen NA, Andersen V, Møller JC, Møller HS, Jessen F, Purup S, Larsen LB. Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis. BMC Gastroenterol. 2012;12:76. [PMID: 22726388 DOI: 10.1186/1471-230x-12-76] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
423 Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. Gut. 2017;66:50-58. [PMID: 26475633 DOI: 10.1136/gutjnl-2015-310393] [Cited by in Crossref: 134] [Cited by in F6Publishing: 126] [Article Influence: 19.1] [Reference Citation Analysis]
424 Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One 2020;15:e0231988. [PMID: 32315368 DOI: 10.1371/journal.pone.0231988] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
425 Pannellini T, Iezzi M, Di Carlo E, Eleuterio E, Coletti A, Modesti A, Rosini S, Neri M, Musiani P. The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis. Int J Immunopathol Pharmacol 2004;17:171-80. [PMID: 15171818 DOI: 10.1177/039463200401700209] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
426 Mitomi H, Okayasu I, Bronner MP, Kanazawa H, Nishiyama Y, Otani Y, Sada M, Tanabe S, Igarashi M, Katsumata T, Saigenji K. Comparative Histologic Assessment of Proctocolectomy Specimens from Japanese and American Patients with Ulcerative Colitis with or Without Dysplasia. Int J Surg Pathol 2005;13:259-65. [DOI: 10.1177/106689690501300305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
427 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
428 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
429 Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779-784. [PMID: 23446338 DOI: 10.1097/mib.0b013e3182802b0e] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
430 Marchal A. Histoséminaire sur les maladies inflammatoires chroniques intestinales (MICI) : cas n o  05 et 06. Annales de Pathologie 2017;37:302-7. [DOI: 10.1016/j.annpat.2017.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
431 Sinhmar GK, Shah NN, Rawal SU, Chokshi NV, Khatri HN, Patel BM, Patel MM. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:565-78. [DOI: 10.1080/21691401.2018.1463232] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
432 Li Z, Arijs I, De Hertogh G, Vermeire S, Noman M, Bullens D, Coorevits L, Sagaert X, Schuit F, Rutgeerts P. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis. 2010;16:1299-1310. [PMID: 20196149 DOI: 10.1002/ibd.21229] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 6.2] [Reference Citation Analysis]
433 Prossomariti A, Scaioli E, Piazzi G, Fazio C, Bellanova M, Biagi E, Candela M, Brigidi P, Consolandi C, Balbi T, Chieco P, Munarini A, Pariali M, Minguzzi M, Bazzoli F, Belluzzi A, Ricciardiello L. Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Sci Rep 2017;7:7458. [PMID: 28785079 DOI: 10.1038/s41598-017-07992-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
434 Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Löfberg R, von Stein OD. Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity: . Inflammatory Bowel Diseases 2013;19:283-92. [DOI: 10.1002/ibd.23019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
435 Rodríguez-lago I, Ramírez C, Merino O, Azagra I, Maiz A, Zapata E, Higuera R, Montalvo I, Fernández-calderón M, Arreba P, Carrascosa J, Iriarte A, Muñoz-navas M, Cabriada JL, Barreiro-de Acosta M. Early microscopic findings in preclinical inflammatory bowel disease. Digestive and Liver Disease 2020;52:1467-72. [DOI: 10.1016/j.dld.2020.05.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
436 Lee SH, Lee HR, Kwon JY, Jung K, Kim SY, Cho KH, Choi J, Lee HH, Lee BI, Jue DM, Cho ML. A20 ameliorates inflammatory bowel disease in mice via inhibiting NF-κB and STAT3 activation. Immunol Lett 2018;198:44-51. [PMID: 29608924 DOI: 10.1016/j.imlet.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
437 Casellas F, Antolín M, Varela E, García-Lafuente A, Guarner F, Borruel N, Armengol Miró JR, Malagelada JR. Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2:683-9. [PMID: 15290661 DOI: 10.1016/s1542-3565(04)00291-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
438 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
439 Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MAM, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L, Torres J, Santiago M, Estevinho MM, Danese S, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31274-X. [PMID: 32920215 DOI: 10.1016/j.cgh.2020.09.017] [Reference Citation Analysis]
440 Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, Tanaka T, Yamamoto K. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. American Journal of Gastroenterology 2015;110:873-80. [DOI: 10.1038/ajg.2015.66] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
441 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
442 Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-105; quiz 1340-1. [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
443 Iacucci M, Smith SCL, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Nardone OM, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology 2021;160:1558-1569.e8. [PMID: 33347880 DOI: 10.1053/j.gastro.2020.12.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
444 Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. J Crohns Colitis. 2017;11:1085-1089. [PMID: 28369329 DOI: 10.1093/ecco-jcc/jjx048] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
445 Li Y, Schaarschmidt B, Umutlu L, Forsting M, Demircioglu A, Koch AK, Martin O, Herrmann K, Juette H, Tannapfel A, Langhorst J. 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. Eur J Nucl Med Mol Imaging 2020;47:768-77. [DOI: 10.1007/s00259-019-04535-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
446 Halfvarson J, Ling Lundström M, Lampinen M, Schoultz I, Bodin L, Carlson M. Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients. Scand J Gastroenterol 2020;55:1163-70. [PMID: 32815414 DOI: 10.1080/00365521.2020.1804994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
447 Jangi S, Yoon H, Dulai PS, Valasek M, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther 2020;52:1008-16. [PMID: 33119168 DOI: 10.1111/apt.16026] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
448 Salem MS, Melmed GY. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet? Gastrointest Endosc Clin N Am 2019;29:437-46. [PMID: 31078246 DOI: 10.1016/j.giec.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
449 Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Hussain S, Singh K. Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. Dig Dis Sci 2012;57:1336-40. [PMID: 22350781 DOI: 10.1007/s10620-012-2027-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
450 Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm. 2018;2018:8031328. [PMID: 29849497 DOI: 10.1155/2018/8031328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
451 Soendergaard C, Kvist PH, Seidelin JB, Pelzer H, Nielsen OH. Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. J Gastroenterol 2016;51:796-807. [PMID: 26660730 DOI: 10.1007/s00535-015-1152-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
452 Akhrieva KM, Kogan EA, Tertychnyi AS, Radenska-Lopovok SG, Zayratyants OV, Selivanova LS. [A new look at colonic mucosal structural rearrangement and the stages of chronic colitis]. Arkh Patol 2021;83:14-9. [PMID: 34859981 DOI: 10.17116/patol20218306114] [Reference Citation Analysis]
453 De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis 2012;18:1127-36. [PMID: 21987487 DOI: 10.1002/ibd.21894] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
454 Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 2002;97:360-369. [PMID: 11866274 DOI: 10.1111/j.1572-0241.2002.05470.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
455 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
456 Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 2006;55:1568-1574. [PMID: 16603634 DOI: 10.1136/gut.2005.089854] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
457 Fabian O, Hradsky O, Lerchova T, Mikus F, Zamecnik J, Bronsky J. Limited clinical significance of tissue calprotectin levels in bowel mucosa for the prediction of complicated course of the disease in children with ulcerative colitis. Pathol Res Pract 2019;215:152689. [PMID: 31679791 DOI: 10.1016/j.prp.2019.152689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology 2020;159:1262-1275.e7. [PMID: 32585306 DOI: 10.1053/j.gastro.2020.06.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
459 Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11:785-791. [PMID: 28333362 DOI: 10.1093/ecco-jcc/jjx032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
460 Triantafillidis JK, Douvi G, Agrogiannis G, Patsouris E, Gikas A, Papalois AE. Effect of mesalamine and prednisolone on TNBS experimental colitis, following various doses of orally administered iron. Biomed Res Int 2014;2014:648535. [PMID: 24895596 DOI: 10.1155/2014/648535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
461 Söderlund S, Tribukait B, Öst Å, Broström O, Karlén P, Löfberg R, Askling J, Sjöqvist U. Colitis-associated DNA aneuploidy and dysplasia in Crohnʼs disease and risk of colorectal cancer: . Inflammatory Bowel Diseases 2011;17:1101-7. [DOI: 10.1002/ibd.21477] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
462 Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar C, van der Woude CJ. STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis. Mol Med. 2012;18:1412-1419. [PMID: 23154639 DOI: 10.2119/molmed.2012.00277] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
463 Lemmens B, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M, Rutgeerts P, Vermeire S, De Hertogh G. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1194-1201. [PMID: 23518809 DOI: 10.1097/mib.0b013e318280e75f] [Cited by in Crossref: 83] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
464 Mosli MH, Feagan BG, Sandborn WJ, Dʼhaens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75. [PMID: 24412993 DOI: 10.1097/01.MIB.0000437986.00190.71] [Cited by in Crossref: 73] [Cited by in F6Publishing: 22] [Article Influence: 9.1] [Reference Citation Analysis]
465 Kalappurayil NB, Thomas J, Mankuni B, Thomas V. Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. J Clin Diagn Res 2017;11:EC07-11. [PMID: 28511386 DOI: 10.7860/JCDR/2017/22816.9332] [Reference Citation Analysis]
466 Mosnier J, Jarry A, Camdessanché J, Antoine J, Laboisse CL. In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17–mediated tumor necrosis factor α production. Human Pathology 2009;40:1159-67. [DOI: 10.1016/j.humpath.2008.11.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
467 Lobatón T, Azuara D, Rodríguez-Moranta F, Loayza C, Sanjuan X, de Oca J, Fernández-Robles A, Guardiola J, Capellá G. Relationship between methylation and colonic inflammation in inflammatory bowel disease. World J Gastroenterol 2014; 20(30): 10591-10598 [PMID: 25132780 DOI: 10.3748/wjg.v20.i30.10591] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
468 Pilarczyk-Zurek M, Chmielarczyk A, Gosiewski T, Tomusiak A, Adamski P, Zwolinska-Wcislo M, Mach T, Heczko PB, Strus M. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol. 2013;13:61. [PMID: 23566070 DOI: 10.1186/1471-230x-13-61] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
469 Moss AC. The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease. Curr Opin Gastroenterol 2014;30:365-9. [PMID: 24811053 DOI: 10.1097/MOG.0000000000000082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
470 Abdelrazeq AS, Kandiyil N, Botterill ID, Lund JN, Reynolds JR, Holdsworth PJ, Leveson SH. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2008;10:805-13. [PMID: 18005192 DOI: 10.1111/j.1463-1318.2007.01413.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
471 Robles-Medranda C, Oleas R, Valero M, Puga-Tejada M, Soria-Alcívar M, Ospina J, Alvarado-Escobar H, Muñoz-Jurado G, Baquerizo-Burgos J, Pitanga-Lukashok H. Confocal laser endomicroscopy detects colonic inflammation in patients with irritable bowel syndrome: a prospective study. Endosc Int Open 2020;8:E550-7. [PMID: 32258379 DOI: 10.1055/a-1119-6327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
472 Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut. 2002;50 Suppl 3:III37-III42. [PMID: 11953331 DOI: 10.1136/gut.50.suppl_3.iii37] [Cited by in Crossref: 43] [Cited by in F6Publishing: 60] [Article Influence: 2.2] [Reference Citation Analysis]
473 Beloqui A, Coco R, Alhouayek M, Solinís MÁ, Rodríguez-gascón A, Muccioli GG, Préat V. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. International Journal of Pharmaceutics 2013;454:775-83. [DOI: 10.1016/j.ijpharm.2013.05.017] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
474 Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004;53:1806-1812. [PMID: 15542519 DOI: 10.1136/gut.2003.036418] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 3.4] [Reference Citation Analysis]
475 Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929-34.e2. [PMID: 23911875 DOI: 10.1016/j.cgh.2013.07.022] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 11.0] [Reference Citation Analysis]
476 Sznurkowska K, Luty J, Bryl E, Witkowski JM, Hermann-Okoniewska B, Landowski P, Kosek M, Szlagatys-Sidorkiewicz A. Enhancement of Circulating and Intestinal T Regulatory Cells and Their Expression of Helios and Neuropilin-1 in Children with Inflammatory Bowel Disease. J Inflamm Res 2020;13:995-1005. [PMID: 33273840 DOI: 10.2147/JIR.S268484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]